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Abstract 
 
The first part of this thesis describes electrolyte transport through an array of 20 
nm wide, 20 μm long SiO2 nanofluidic transistors. At sufficiently low ionic strength, the 
Debye screening length exceeds the channel width, and ion transport is limited by the 
negatively charged channel surfaces. At source-drain biases > 5 V, the current exhibits a 
sharp, nonlinear increase, with a 20 − 50-fold conductance enhancement. This behavior is 
attributed to a breakdown of the zero-slip condition. Implications for peptide sequencing 
as well as energy conversion devices are discussed. 
The next part describes a technology for the detection of the highly aggressive 
brain cancer glioblastoma multiforme (GBM). In general, proteomic approaches have 
shown great promise in recent years for correctly classifying and diagnosing cancer 
patients. However, no large antibody-based microarray studies have yet been conducted 
to evaluate and validate plasma molecular signatures for detection of glioblastoma and 
monitoring of its response to therapy. In this study, we compared plasma samples from 
46 glioblastoma patients (72 total samples) with those of 47 healthy controls with respect 
to the plasma levels of 35 different proteins known to be generally associated with tumor 
growth, survival, invasion, migration, and immune regulation. Average-linkage 
hierarchical clustering of the patient data stratified the two groups effectively, permitting 
accurate assignment of test samples into either GBM or healthy control groups with a 
sensitivity and specificity as high as 90 % and 94 %, respectively (when test samples 
within unbiased clusters were removed). The accuracy of these assignments improved 
(sensitivity and specificity as high as 94 % and 96 %, respectively) when the cluster 
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analysis was repeated on increasingly trimmed sets of proteins that exhibited the most 
statistically significant (p < 0.05) differential expression. The diagnostic accuracy was 
also higher for test samples that fell into more homogeneous clusters. Intriguingly, test 
samples that fell within perfectly homogeneous clusters (all members belonging to the 
same group) could be diagnosed with 100 % accuracy. Using the same 35-protein panel, 
we then analyzed plasma samples from GBM patients who were treated with the 
chemotherapeutic drug Avastin (Bevacizumab) in an effort to stratify patients based on 
treatment-responsiveness. Specifically, we compared 52 samples from 25 patients who 
exhibited tumor recurrence with 51 samples from 21 patients who did not exhibit 
recurrence. Again, several proteins were highly differentially expressed and cluster 
analysis provided effective stratification of patients between these two groups (sensitivity 
and specificity of 90 % and 96 %, respectively). 
Finally, single-cell resolution patterning of tissue engineered structures is 
demonstrated. The proper functioning of engineered constructs for tissue and organ 
transplantation requires positioning different cell types in anatomically precise 
arrangements that mimic their configurations in native tissues. Toward this end, 
microfabrication strategies have facilitated great strides in cell micropatterning in recent 
years, but these technologies are still limited in that they can typically only pattern one or 
two cell types at a time with feature sizes that are larger than a single cell. We present a 
patterning methodology that allows for high-density, multiplexed patterning of distinct 
cell types on glass at single-cell resolution.  The technique involves two microfluidic-
patterning steps run perpendicularly to each other in which “anchor” oligos are first laid 
down on a polylysine-coated glass substrate followed by binding of “bridging” oligos 
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containing both an anchor-complementary sequence and a unique sequence that can bind 
to an oligo-functionalized cell. In this manner, dense arrays of 3 x 3 and 3 x 1 DNA grids 
can be patterned and then converted into cell arrays. As a proof-of-concept, both a 
neuron-astrocyte construct and a pancreatic islet construct containing 2 distinct islet cell 
types were patterned separately as a dense array of cell grids. Once fixed in a hydrogel 
matrix, layers of patterned cells were then stacked to form 3-D tissue engineered 
constructs. 
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Chapter 1 
Introduction 
 
 
1.1 Protein Analysis and Proteomics 
The last decade has witnessed substantial advancements in technologies 
developed for faster and more comprehensive protein sequencing1-3, analysis of protein 
structure and function4,5, and profiling of proteins involved in human diseases such as 
cancer6-8.  Efforts to determine increasingly complex sequences and structures of proteins 
within a rapid timeframe have been led by improvements in mass spectrometry6,9, a 
technology that has proven far superior to the days when the Edman Degradation was the 
only method for sequencing peptides.  To help gain insight into the molecular basis of 
diseases, technologies such as the enzyme-linked immunosorbent assay (ELISA)10, and 
gel chromatography11, as well as mass spectrometry, have allowed for the analysis of 
large amounts of protein data, proving indispensable in detecting protein expression from 
human tissue and blood.  Indeed, the field of proteomics owes its existence to these 
technologies. 
2 
 
However, the shortcomings of these analytical devices are beginning to be 
realized as the need for measuring ever increasing amounts of biological information will 
require higher throughput and lower cost processes.  As such, the field has pushed toward 
miniaturization of these technologies to the micro- and nanoscale7,12. Using inexpensive, 
yet robust materials to build biochips will allow information on protein sequences, 
structures, and functions to increase by orders of magnitude.  At the same time, these 
analyses would occur a great deal faster than current methods allow. 
These microchip technologies would also boost large scale proteomic studies, 
which would be especially useful in treating cancer, since gaining information about the 
disease depends on understanding interactions between many proteins13,14.  For example, 
the rapid detection of the levels of thousands of human blood proteins at low cost could 
be realized in a minimally invasive at home diagnostic device for the early detection of 
cancer.  By the same token, a related device could help diagnose a multitude of diseases 
in the third world, where access to healthcare is limited. 
In both the academic setting and the biotechnology industry, processes that 
require entire laboratories could be scaled down to the size of a chip.  At the same time, 
the extensive parallelization enabled by such small devices would vastly increase 
throughput. 
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1.2 Nanoscale Protein Sequencing Devices 
 As researchers have worked on elucidating the structures and functions of 
proteins, simple nanoscale devices have been designed toward sequencing these proteins 
faster and more efficiently, without the need for fluorescent labels and expensive optical 
devices for imaging.  Some examples of these contraptions include fabricated 
nanopores15-17 (Figure 1.1) and nanofluidic channels18-20 (Figure 1.2), as well as 
synthetic and naturally occurring nanoporous materials integrated into new designs21 
(Figure 1.3). 
 
Metal electrodes are usually attached to either side of the nanopores or 
nanochannels, and voltage biases between the electrodes modulate the electric field 
within.  As these technologies are refined, it is anticipated that the interaction of the 
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electric field with charges along an unknown biomolecule could result in an electrical 
readout that would identify the analyte.  Multiple efforts are currently underway on using 
these devices to sequence DNA molecules rapidly and in real time, with the expectation 
that entire genomes could be sequenced at low cost.  The personal genetic codes obtained 
could advance personalized medicine by the creation of new drugs capable of treating far more 
specific illnesses, and they could help determine a person's predisposition to particular diseases. 
 
However, as research into personalized medicine has progressed, it has moved toward 
identifying protein signatures to diagnose human diseases.  Accordingly, in the near future, 
protein sequencing devices will have to follow suit and find applications in the analysis of 
proteins rather than DNA. 
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1.3 Plasma Protein Profiling for the Detection of Cancer  
The rapid expansion of the field of proteomics has made it necessary to develop 
technologies capable of analyzing complex proteomes, specifically the levels and 
interactions of differentially expressed proteins in the human body.  In particular, the 
ability to measure these on a systemic level in a noninvasive and cost-effective manner 
has brought great interest to the detection of cancer biomarkers found in the blood22-25. 
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The current gold standard for the high sensitivity identification and measurement 
of proteins found in plasma, the blood component in which proteins are dissolved, is the 
sandwich ELISA26. In this assay, a layer of capture antibodies specific to the antigen of 
interest adheres to a solid support, usually contained within a 96 well microtiter plate.  
Another layer of detection antibodies conjugated to an enzyme “sandwiches” the antigen, 
and the addition of an enzyme substrate quantifies the level of antigen. Although the 
standard ELISA exhibits great sensitivity, its drawback is that it can only measure a 
relatively small number of analytes, as each well is devoted to one protein. Therefore, its 
limitations in cancer diagnostics are becoming more apparent as most cancers are now 
known to affect large panels of proteins rather than any single marker. 
The recent advent of multiplexed platforms for protein detection, such as antibody 
microarrays (Figure 1.4), has shown great promise for large scale plasma protein 
profiling6,26-28. The method of detection is similar to the ELISA, as antigens are 
sandwiched between two layers of antibodies. However, the capture antibodies are 
immobilized on-chip, using either microarray spotters or microfluidic flow patterning, to 
create spots a few hundred microns in diameter. Thus, it is possible to create hundreds of 
separate protein detection regions in an area equal to that of a typical ELISA well. 
Furthermore, the detection antibodies can be conjugated to fluorescent molecules or 
covalently linked to nanoparticles, resulting in even higher sensitivity. Streamlined 
variations of such multiplexed devices will prove vital in the early stage detection of 
multiple types of cancer. 
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1.4 Thesis Synopsis 
The overall theme of this thesis centers on the development of new technologies 
for high throughput analysis of proteins. Chapter 2 begins with a description of the 
construction of silica nanofluidic channels using semiconductor fabrication methods and 
concludes with their applications to peptide sequencing. The entire nanochannel device 
consists of an array of 20 nm-wide, 20 µm-long channels in close proximity to a gate 
electrode along with microfluidic channels that cross perpendicularly at the nanochannel 
ends. Ionic solutions, such as potassium chloride (KCl), and peptide solutions, such as 
polylysine and polyaspartate, are flowed into the device, and source-drain biases are 
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applied across the nanochannels to study the characteristics of the current produced by 
the particular charged species. For KCl, at sufficiently low ionic strength, the Debye 
screening length exceeds the channel width, and ion transport is limited by the negatively 
charged silica channel surfaces so that only positively charged species can flow through 
the channels. At source-drain biases > 5 V, the current exhibits a sharp, nonlinear 
increase, with a 20 – 50-fold conductance enhancement. This behavior is attributed to a 
breakdown of the zero-slip condition. This phenomenon results in amino acid specific I-
V traces when aspartate and lysine monomer solutions are added separately, which shows 
great promise for the use of nanofluidic channel devices for high throughput protein 
sequencing and structure determination. Chapter 2 has been taken in part from © Nano 
Lett., 2009, 9(4), 1315-131929. 
Chapter 3 delves into the field of proteomics and presents a diagnostic device for 
the detection of differentially expressed proteins in the blood of patients with 
glioblastoma multiforme (GBM), the most common and aggressive class of brain cancer 
in humans.  The device architecture improves on recently developed antibody 
microarrays in terms of device stability and longevity and consists of DNA encoded 
antibody libraries (DEAL), whereby orthogonal sets of anchor single-stranded DNA 
oligomers are spotted onto polylysine borosilicate slides and their complementary 
oligomers are conjugated to antibodies and hybridized to the anchor strands.  Plasma 
samples from both GBM patients and healthy controls are positioned onto the array, 
followed by the addition of secondary antibodies and fluorescent markers to allow 
detection of the levels of cancer biomarkers.  The chapter then discusses investigations 
into the effects of the vascular endothelial growth factor (VEGF) inhibitor Avastin on the 
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plasma protein profile of glioblastoma patients with actively growing tumors vs. non-
growing tumors. 
Lastly, Chapter 4 presents a variation on the DEAL technology for the creation of 
ultra-high density oligonucleotide arrays for the assembly of tissue engineered structures 
with single cell resolution.  The creation of oligonucleotide spots 10 μm x 10 μm in size 
and 30 μm in pitch is achieved using a microfluidic flow patterning technique to arrange 
single-stranded bridge oligo sequences onto complementary anchor sequences. Cells are 
then coded with single-stranded oligos complementary to specific bridge sequences and 
allowed to hybridize. Single cell resolution patterns of human neurons and astrocytes and, 
separately, mouse pancreatic islet cells are illustrated and shown to be viable.  The 
advantage of such a technology is that it has the potential to allow for the assembly of 
any tissue from scratch in virtually any pattern imaginable. 
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Chapter 2 
Fast Nonlinear Ion Transport via Field-Induced 
Hydrodynamic Slip in Sub-20 nm Hydrophilic 
Nanofluidic Transistors 
 
 
2.1 Introduction 
 Recently, novel fluid-mechanical phenomena have been observed as the 
dimensions of fluidic channels have approached the nanometer scale. Theoretical 
models1-4 and experimental demonstrations5-7 of finite hydrodynamic slip in hydrophobic 
nanochannels have received considerable attention; however, experimental evidence of 
slip in hydrophilic nanochannels is nonexistent. Here we report on ion transport through 
an array of 20 nm-radius, 20 µm-long hydrophilic SiO2 nanofluidic transistors. Above a 
threshold source-drain bias, channel conductances are enhanced up to 50-fold over 
expected values. The improved ion transport is interpreted as arising due to an electric 
field-induced breakdown of the zero-slip boundary condition. The slip length can be 
tuned by modulating the surface-charge density of the nanochannels via application of a 
gate voltage. This phenomenon results in amino acid specific I-V traces when lysine and 
aspartate monomer solutions are added separately, which demonstrates the potential for 
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the use of nanofluidic channel devices for high throughput protein sequencing and 
structure determination. The presence of finite slip results in a ~106-fold increase in 
mechanical power output, and thus also shows promise for efficient energy conversion, 
filtration, and desalination applications. 
The relatively recent emergence of nanochannel fabrication methods8-10 has 
allowed electrokinetic phenomena to be investigated in nanofluidic systems, and has 
created renewed interest in the potential of fluidic devices for energy conversion and 
other tasks. As the Debye screening length approaches the scale of the channel 
dimensions, the surface charge dominates the electrokinetic flow behavior within the 
channel, controlling the concentration of electrolytes11-16 such that unipolar counterions 
dominate current flow (Figure 2.1). This phenomenon can potentially be harnessed for 
mechanical-to-electrical energy conversion by using pressure to drive a streaming current 
through the nanochannel. Alternatively, electrical-to-mechanical energy conversion is 
possible by applying an electric field across the length of the nanochannel, thereby 
driving fluid through by electroosmosis17-19. However, current flow through nanofluidic 
channels at a given pressure, or source-drain voltage, is severely limited due to the no-
slip boundary condition that characterizes most such systems. This boundary condition 
represents the fact that there is no fluid or ion flow at the liquid/channel interface. The 
counterion density is highest at this interface, but because these counterions are 
immobilized by surface charges, those ions do not contribute to the current, resulting in 
low energy conversion efficiencies. 
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The no-slip boundary condition is not a fundamental limitation, however, and 
systems with finite slip have received recent attention20,21. Slip velocity (υslip) is 
proportional to the shear rate, according to the following equation: 
 υslip = b(dυ/dx)|surf. 
Here, υ is the fluid velocity, x is the coordinate normal to the surface, and b is the slip 
length, or the distance into the surface where υ extrapolates to zero.   
A number of theoretical studies21,22 have revealed that mechanical-to-electrical 
energy conversion efficiencies can be very high, even approaching 100 %, for nanofluidic 
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channels exhibiting a large b. These studies have focused on streaming currents through 
smooth, hydrophobic nanofluidic channels, since such systems are thought to exhibit the 
greatest potential for slip. For example, Ren and Stein21 have calculated that, for a 10 nm 
high slit-shaped, hydrophobic nanochannel, 40 % energy conversion efficiencies are 
realistic for b values of 30 nm. Indeed, very large slip lengths have been measured in 
carbon nanotube-based nanofluidic channels5,7. However such devices may not be 
suitable for energy conversion since the lack of surface charges prevents the creation of 
an intrachannel unipolar environment essential for mechanical-to-electrical energy 
conversion. Currently, most nanofluidic channels are fabricated from silica or other 
materials that yield charged and/or hydrophilic surfaces. Due to the strong attraction of 
Stern layer counterions to such hydrophilic surfaces, the no-slip condition is difficult to 
overcome. For example, Dekker’s group has measured energy conversion in hydrophilic 
nanochannels under no-slip conditions, and found a conversion efficiency of only 3 %23. 
They calculated a maximum conversion efficiency of 12 % for similar monovalent ions 
in water22. Much greater conversion efficiencies will be needed for practical technologies 
to be realized. If the no-slip boundary condition in hydrophilic channels could be 
surmounted, greatly enhanced streaming currents and energy conversion efficiencies 
would be possible in such systems, making energy conversion applications far more 
feasible.  
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 2.2 Experimental Methods 
  In this chapter, we report on the electrokinetics of potassium chloride (KCl) ion 
transport through nanofluidic transistors comprised of arrays of oval shaped, hydrophilic, 
silica nanochannels. Although ion transport has been investigated previously in a single 
SiO2 nanofluidic channel10 with similarly small dimensions, our fabrication method24 
produces sufficiently large numbers of closely spaced SiO2 nanochannels such that 
currents can be measured even at very low KCl molarities ([KCl] = 10-7 M).   
The experimental setup is shown in Figure 2.2. The nanofluidic device consisted 
of a 20 micrometer-long array of 80 parallel, 20 nm × 30 nm cross section silica channels 
built from a template of silicon nanowires fabricated using the SNAP method24 (Figure 
2.2b,c). An indium tin oxide (ITO) gate electrode is deposited on top of the array, with a 
silica gate oxide layer sandwiched in between. As shown in Figure 2.2c, extremely 
narrow (~3 nm) channels between the primary channels were observed. These likely arise 
from a SiO2 deposition process that is not 100 % conformal. However, the voids are far 
smaller than the primary nanochannels and their contribution to the ionic current should 
be negligible. The nanochannels interface with two sets of microfluidic channels that act 
as reservoirs for electrolyte solutions.  The device is sealed with a slab of plasma-bonded 
PDMS to isolate the microfluidic channels and prevent leakage current. Finally, holes are 
punched into the PDMS to allow the insertion of Ag/AgCl electrodes into the 
microfluidic channels for current measurements. The detailed fabrication processes are 
described in the Appendix.  The SNAP-based nanochannel fabrication method is robust, 
allowing devices to be consistently generated with nearly 100 % yield.  
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2.3 Results and Discussion 
2.3.1 Slip-enhanced ion transport through nanofluidic channels 
Upon completion of device fabrication, we introduced aqueous solutions of KCl 
into the device at concentrations ranging from 10-7 M to 10-1 M, optically observed 
nanochannel filling over the entire array, and measured the source-drain current-voltage 
(ISD-VSD) characteristics over a 30 – 50 volt range  (conductance plots (dISD/dVSD) at the 
abovementioned KCl concentrations are presented in the Appendix). Similar to previous 
studies12,13, which were limited to conductance measurements at low bias (< 5 V), 
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conductance saturation is present below a threshold concentration of 10-3 M. This 
saturation occurs because the negatively charged silanol groups at the SiO2 nanochannel 
surface attract K+ counterions and repel Cl- anions over the characteristic Debye length 
(κ-1), which is given by25: 
 κ-1 = [εkBT/(e2NAΣiciZi2)]1/2.  
Here, ci is the molar concentration and Zi is the valence of ion species i. Standard 
constants include ε (the permittivity), kB (Boltzmann constant), e (electron charge), and 
NA (Avogadro’s number). For [KCl] = 10-3 M, this gives a Debye length of 9.7 nm, which 
is comparable to the 10 nm radius of our nanochannels. As a result, the K+ concentration 
within our nanochannels is determined by the surface charge on the walls for bulk [KCl] 
≤ 10-3 M. On the other hand, for [KCl] > 10-3 M, the Debye length becomes smaller than 
the nanochannel radius, leading to shielding of surface charges and more ohmic ion 
transport behavior (Figure 2.3b). 
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In the surface charge-governed ion transport regime, [KCl] ≤ 10 -3 M, and for VSD 
values above a threshold voltage (VT) of about 5 V, the current exhibits a sharp and 
nonlinear increase with increasing bias (Figure 2.3a) and conductance enhancement of 
20-50 fold, depending upon [KCl]. We propose that this nonlinear behavior arises from 
an electric field-induced breakdown of the zero-slip condition. The transition into the 
finite-slip regime can be attributed to the changing behavior of the K+ ion double layer in 
the nanochannel solution. The layer closest to the surface, called the Stern layer, is about 
0.3 nm thick26 and consists of K+ ions immobilized to the nanochannel surface. The 
second layer, which can move under no-slip conditions, is a diffuse layer of K+ ions that 
comprises the rest of the solution within the nanochannels27 (Figure 2.4a). 
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However, it has been theorized that the Stern layer can be moved tangential to the 
surface under the influence of an external electric field2,26 (Figure 2.4b). In our device, 
this may be happening above the threshold VSD, in which case the electric field parallel to 
the nanochannel surface is overcoming the attraction of the Stern layer K+ ions to the 
silica surface. As a result, these ions move along the surface, electroosmotically pulling 
water with them, and the zero-slip condition no longer holds. Due to viscous forces, 
hydrodynamic slip at the nanochannel surface increases the velocity of all species within 
the nanochannel, resulting in greatly enhanced conductance as illustrated in Figure 2.4b 
as well as in the schematic diagrams in Figure 2.3a.   
Nonlinear I-V characteristics in somewhat larger (40 nm deep) nanofluidic 
channels for sodium phosphate concentrations in the range 10-4 – 10-2 M have been 
observed by Kim, et al9.  However, their results reflect very different physics. They 
observed a broad, current-saturated, intermediate bias region separating their low- and 
high-bias regions. They interpret their data within the framework of concentration 
polarization, in which an ion depletion region develops at the microchannel/nanochannel 
interface, which leads to the current saturation regime in their ISD-VSD plots. At 
sufficiently high bias, instabilities (imaged as vortices) appear at the 
microchannel/nanochannel interface, collapsing the depletion regions, and resulting in a 
second phase of steep current increase (the overlimiting region). At even higher bias, 
conductance values return to their original (low-bias) levels. The lack of a current-
saturated region in our data, the fact that conductances remain high and stable as VSD 
increases, the absence of nonlinear ion transport above 10-3 M, and the below-described 
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voltage-gating experiments all distinguish our system and support the interpretation of 
non-zero slip in our channels. 
 
2.3.2 Nanochannel ion transport model 
The contribution of slip to conductance enhancement within a nanochannel of 
radius comparable to the Debye screening length can be modeled as follows (see 
Appendix for detailed description). To maintain electroneutrality, the nanochannel 
surface charge must equal the counterion charge in the solution (Qsurface = Qsolution). This 
is expressed as: 
A × σ = V × e × ncr                                             (1), 
where A is the nanochannel surface area, σ is the surface charge density, V is the 
nanochannel volume, and ncr is the critical ion density at which nanochannel ion 
transport transitions from bulk-like to a surface-charge governed regime (herein, ncr is 
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equivalent to a K+ concentration of  ~10-3 M). The value of σ obtained is 0.0006 C/m2.  
Using this value, the slip length b can be calculated using the conductance equation: 
G = N × 4 µ σ  (d/L) (1 + b/lstern)                        (2),   
where µ is the K+ mobility (= 7.6×10-8 m2/(V·s)), d is the nanochannel hydraulic diameter 
(= 24 nm), L is the nanochannel length (=20 micrometers), N is the number of 
nanochannels (80) in the array, and lstern is the thickness of the Stern layer (~0.3 nm), 
which is also the distance over which the shear plane moves when shifting from no-slip 
to slip conditions. The first part of equation (2), N × 4 µ σ (d/L), represents electrokinetic 
conductance through the nanochannels in the absence of slip, and the (1 + b/ lstern) factor 
represents the conductance enhancement due to slip1,2. For conductance in the low bias 
(VSD < VT) regime, where there is no slip (b = 0), the measured conductance (~14.4 pS) is 
almost identical to the value calculated (~16.8 pS) using equations (1) and (2). 
2.3.3 Tuning the nanochannel surface charge density by application of gate voltages 
If the emergence of hydrodynamic slip is indeed a consequence of a field-induced 
breakdown in electrostatic attractions between the Stern layer and the channel wall, 
reducing the surface charge density should lower this electrostatic barrier and enhance 
slip. This reasoning is supported by two observations. First, there is no significant 
difference either in slip length or in the threshold voltage at which slip occurs for all 
values of [KCl] ≤  10-3 M (Figure 2.3c). This is attributable to the fact that the surface 
charge density remains fairly stable throughout these concentrations. Additional support 
stems from experiments that exploit a gate electrode to tune the nanochannel surface 
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charge density and measure the corresponding change in slip length. The gating 
experiments on a 10-4 M KCl solution are presented in Figure 2.5.   
Another noteworthy observation is the reversal in the effect of Vg on conductance 
between the low bias and high bias regimes. As Vg becomes more positive, the bare 
surface charge density (σ) extracted from equation (1) becomes less negative (Figure 
2.5b), which has two potentially competing effects. The first is a decrease in the 
intrachannel counterion concentration, which tends to decrease the conductance. The 
second is a decrease in the attraction of the Stern layer to the channel surface, which 
tends to increase the conductance (due to slip). At low source-drain bias (VSD < VT), the 
electric field is not strong enough to overcome the attraction of the Stern layer to the 
surface, so the decrease in ion concentration with increased Vg (Figure 2.5a inset) 
translates directly to a decreased conductance, as shown in previous studies11,12. By 
contrast, in the high source-drain bias (VSD > VT) regime, the electric field is strong 
enough to move the Stern layer. Therefore, as Vg becomes more positive, the Stern layer 
moves faster (larger slip length, b) (Figure 2.5c), resulting in a net increase in 
conductance. Alternatively, less force is required to begin moving the Stern layer (lower 
VT) as its attraction to the channel surface decreases with more positive Vg. 
Over the entire range of VSD, the nonlinear nature of the I-V curves is evident for 
all values of Vg (Figure 2.5a). In the low bias regime (VSD < VT), where there is no slip, 
the ohmic response is well-described by the conductance equation without the 
enhancement factor (notice that the enhancement factor reduces to unity for b = 0) as 
shown in the Appendix. In the high VSD regime (VSD > VT), these curves were fitted with 
the full conductance equation including the slip enhancement term illustrated in equation 
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(2). Such linear fits permitted us to extract the slip length, b, for each value of Vg (Figure 
2.5c). Our obtained slip lengths in the range of ~2 – 10 nm are comparable to those 
proposed in studies of SiO2 surfaces28 and represent on average 8 – 35-fold increases in 
conductance. 
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2.3.4 Peptide sequencing 
A 10-4 M solution of aspartic acid monomers at a pH of 5.5 was inserted into the 
nanochannel array, and I-V curves were obtained. The device fabrication and 
measurement setup were identical to those used in I-V measurements with KCl. The data 
for the amino acid species under varying gate voltages (Figure 2.6a) is similar to that 
seen with 10-4 M KCl, with enhanced ion transport occurring above a threshold voltage, 
but, for aspartic acid, this increase is only observed under the influence of a positive gate 
voltage.  For Vg = 0, the conductance is just starting to increase at VSD above |±20 V|, and 
for Vg < 0, this phenomenon is completely suppressed at all values of VSD. At low source-
drain bias, decreasing conductance with increasing Vg parallels the behavior of KCl 
(Figure. 2.6a inset) and emphasizes the opposite trend in conductance vs. gate voltage at 
low and high source-drain bias. The slip lengths range from 0 – 8 nm (Figure 2.6b), 
values that are comparable to those seen with KCl, although the suppression of the slip 
length at negative gate voltages is not seen with KCl under the VSD range measured.  
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However, the similarities between the measurements of the aspartic acid and KCl 
solutions indicate that positive ions are the dominant charge carriers in the aspartic acid 
solution. Above a pH of ~3.9, the majority of aspartic acid monomers are deprotonated, 
giving negatively charged aspartate ions and positive hydronium ions. The negative 
surface charge of the nanochannels with the ensuing Debye length on the order of the 
nanochannel radius prevents the entry of aspartate ions, in which case conductance is 
dominated by hydronium ions.  
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A similar experiment was also conducted on a 10-4 M solution of lysine monomers 
at a pH of 9.0 (Figure 2.7). Here, enhanced ion transport above a threshold voltage was 
observed as well, however the threshold voltage was considerably higher than for 
aspartate and was only significantly observed for Vg > +5 V (Figure 2.7a). Even at these 
positive gate voltages, the conductance just starts to increase at VSD above |±30 V|, 
resulting in slip lengths that range from 0 – 5 nm (Figure 2.7b). Also, the values of the 
current are about an order of magnitude smaller than those seen for aspartate, signifying 
that the conducting species must be considerably larger in this case. Given these 
observations and the fact that below a pH of ~ 10.5, the majority of lysine monomers are 
protonated, positively charged lysine monomers are most likely the major conducting 
species. With the differences in I-V characteristics and slip lengths seen for aspartate and 
lysine, nanofluidic channels have great potential for identifying all the other amino acids 
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based on mass and pKa value. Once this is achieved, the obvious next step would be to 
sequence peptides.  
2.3.5 Mechanical power enhancement 
The ability to access finite-slip conditions in these nanochannels is encouraging 
from the point-of-view of energy conversion. We consider the mechanical power output 
of our device. This is the kinetic energy per unit time that is associated with the 
electroosmotic movement of fluid through the nanochannel array: 
Mechanical Power = (1/2)(ρυeofA) υeof 2        (3), 
where υeof is the electroosmotic fluid velocity of water through the nanochannels, and 
ρυeofA is the mass flow rate. According to equation (3), the mechanical power increases 
as the cube of the electroosmotic fluid velocity. Therefore, an 80 – 200-fold increase in 
fluid velocity, as calculated in our device due to slip, translates to a ~106 enhancement in 
mechanical power. Detailed calculations on electroosmotic fluid velocity enhancements 
extracted from current measured in the nanochannel array device and their correlation to 
mechanical power are described in the Appendix. Such a large improvement in 
mechanical power through these silica channels suggests that they may also be useful for 
certain applications outside of peptide sequencing for which nanofluidic devices have 
been targeted, such as filtration and water desalination.   
Based on our results showing enhanced ion transport, silica-based nanofluidic 
devices would likely exhibit a higher mechanical-to-electrical energy conversion 
efficiency than the current measured limit of 3 %23. In a recent work by Ren and Stein21, 
theoretical characterization of electrokinetic transport through nanochannels showed that 
30 
 
streaming current increases dramatically with increases in slip length, predicting > 70 % 
energy conversion efficiencies. The ability to tune slip lengths with gate voltages should 
permit the testing of this theory in future experiments. Measurements of streaming 
currents through nanochannels will require a slight modification of our device design, 
since the PDMS/silica interface cannot tolerate high pressures.   
 
2.4 Conclusion 
In summary, we have investigated ion and amino acid transport through an array 
of 80 closely-spaced sub-20 nm hydrophilic SiO2 nanochannels over a 30 – 50 V range of 
source-drain biases. We have observed that for ion concentrations at which the Debye 
length exceeds the nanochannel radius, ion transport becomes greatly magnified at a 
threshold source-drain bias. This behavior can be described by a theoretical model that 
attributes the enhancement to a breakdown of the no-slip boundary condition at the 
liquid/nanochannel surface interface at high source-drain bias. By varying the surface 
charge density of the nanochannels using a gate electrode, we were able to tune the slip 
length to obtain further enhancements in ion transport through the hydrophilic 
nanochannel array. Using this technique, we were also able to obtain specific I-V 
characteristics for two different amino acids, aspartate and lysine. These results imply 
that such devices have the potential to be utilized for protein sequencing and structure 
determination and can be harnessed for efficient energy conversion applications.  
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2.6 Appendix A: Nanochannel Fabrication and Measurement 
 
 
The first step in building nanochannels (Figure 2.8) was to generate a nanowire 
template. The SNAP method24 and standard electron beam lithography (EBL) were used 
to make an array of silicon nanowires on a transparent quartz substrate with a 30 nm-
thick amorphous silicon layer deposited using an e-beam evaporator. In the silicon 
nanowire array generated by the SNAP method, each wire was about 15 – 20 nm-wide 
with a pitch of 50 nm. The wires were sectioned into regions 20 µm in length and 5 µm in 
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width by standard electron beam lithography (EBL). Low Pressure Chemical Vapor 
Deposition (LPCVD) was then used to deposit a 40 nm-thick silicon dioxide gate oxide 
layer on top of and between the wires according to the reaction: SiH4 + O2 → SiO2 + 2H2. 
A 50 nm-thick layer of indium tin oxide (ITO) was sputtered on top of the low 
temperature oxide (LTO), patterned with photoresist, and etched with a 0.5 M HCl 
solution to create the gate electrode. A 5 µm-thick layer of LTO was deposited on top of 
the device. Photoresist was spun onto the LTO layer and a microchannel pattern was 
made by photolithography. The pattern was etched down via an Active Oxide Etching 
(AOE) process (CHF3:C4F8:Ar = 33 sccm:7 sccm:10 sccm, 200 W, 10 mTorr, 15 
minutes) to expose the ends of the SNAP wires. This gave a set of microchannels 
connecting either end of the SNAP wires. The microchannel depth was about 5.5 µm as 
confirmed by a surface profiler (Dektak 150). The photoresist was stripped by acetone, 
and the substrate was further cleaned by a piranha solution (H2SO4: H2O2 = 5:1 by 
volume). At this point, XeF2 was used to selectively and isotropically etch the silicon 
wires to form hollow channels within the glass according to the reaction: 2XeF2 + Si → 
SiF4(g) + 2Xe(g). Before loading substrates into the XeF2 etching chamber, the substrates 
were dipped into a buffered oxide etching solution (BOE: NH4F/HF= 6:1 by volume) for 
1 second to remove native oxide layers on the exposed tips of the silicon wires. The 
pressure of XeF2 gas was maintained at about 2800 mTorr during the etching procedures. 
The etching progress was monitored by a color change in the array as viewed by optical 
microscopy. Finally, PDMS with drilled input/output holes was bonded to the device by 
using an oxygen plasma technique to create a watertight seal between the microchannels. 
This seal ensures that the only connection between the microchannels is via the 
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nanochannels. Ionic solutions were inserted through the input holes in the PDMS, and the 
ionic current measurements were carried out with the use of a source/preamplifier unit 
(Keithley 2400). Commercially available Ag/AgCl electrode assemblies (E. W. Wright) 
were used. The ensuing electrokinetic current could be read, thereby allowing the 
characterization of ionic transport through the nanochannels. 
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2.7 Appendix B: Conductance Equation Derivation 
 
 
The contribution of slip to conductance enhancement within a nanochannel of 
radius comparable to the Debye screening length can be modeled as follows. To maintain 
electroneutrality, the nanochannel surface charge must equal the counterion charge in the 
solution. This is expressed as: 
Qsurface = Qsolution                           (eq. A1). 
This fundamental equation can be expanded to show its components, which gives: 
 A × σ = V × e × (nK + nCl)                            (eq. A2), 
where A is the nanochannel surface area, σ is the surface charge density, V is the 
nanochannel volume, e is the electron charge, and nK and nCl are the K+ and Cl- ion 
densities, respectively. For [KCl] ≤ 10-3 M, the interior of the nanochannel is virtually 
unipolar, made up almost entirely of K+ ions, so that the term nCl becomes negligible. 
The factor nK + nCl can then be approximated as the parameter ncr, which is defined as 
the critical ion density within the nanochannel at which ion transport transitions from 
bulk-like to a surface charge-governed regime (herein, ncr is equivalent to a K+ 
concentration of ~10-3 M). Using these conditions along with eq. A2, the surface charge 
density (σ) of a single nanochannel for [KCl]bulk ≤ 10-3 M is estimated as a function of ncr 
by 
                     (eq. A3), 
 
σ =
V × e × ncr
A
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which gives a value of 0.0006 C/m2. From the ion density, it is possible to find the 
current (I) associated with ion transport through a nanochannel, which is approximated 
as29 
I = e × n × µ × E × S               (eq. A4), 
where n is the ion density, µ is the K+ mobility (= 7.6×10-8 m2/(V·s)), E is the electric 
field defined by source-drain voltage/nanochannel length (VSD/L), and S is the cross-
sectional area of the nanochannel. The conductance (G) of the nanochannel array in the 
surface charge-governed regime at low source-drain bias is obtained by taking the 
derivative of the current with respect to source-drain voltage (VSD), treating the ion 
density (n) as ncr, and using eq. A3 to make the conductance a function of the surface 
charge density, which gives 
  G = N × 4 µ σ (d/L)                (eq. A5), 
where d is the nanochannel hydraulic diameter (= 24 nm), L is the nanochannel length (= 
20 micrometers), and N is the number of nanochannels (80) in the array. To account for 
enhanced ion transport at high source-drain bias, eq. A5 is modified to 
G = N × 4 µ σ (d/L) (1 + b/lstern)                   (eq. A6), 
where b is the extrapolated slip length, and lstern is the thickness of the Stern layer (~0.3 
nm), which is also the distance over which the shear plane moves when shifting from no-
slip to slip conditions. The relation shown in eq. A5, G = N × 4μσ(d/L), represents 
electrokinetic conductance through the nanochannels without considering slip (b = 0), as 
shown in Figure 2.9. The extra term, 1 + b/lstern, presented in eq. A6, represents the 
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conductance enhancement due to slip1,2. For conductance in the zero-slip regime, the 
measured conductance (~14.4 pS) was almost identical to the value (~16.8 pS) obtained 
using eqs. A3 and A5. 
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2.8 Appendix C: Mechanical Power Calculations 
 
The mechanical power output of the device – the kinetic energy per unit time 
associated with electroosmotic movement of fluid through the nanochannel – is defined 
by 
 
where υeof is the electroosmotic flow velocity, ρ is the fluid density, A is the cross-
sectional area, and ρυeofA is the mass flow rate. To obtain the mechanical power output 
enhancement from the nanochannel device at high electric fields, we first calculate the 
electroosmotic flow velocity (υeof) of a KCl solution with a saturated nanochannel 
concentration of 10-3 M in the low voltage no-slip region and in the absence of a gate 
voltage by applying the Helmholtz-Smoluchowski equation30: 
 
with η the viscosity of water, ε the permittivity, and E the electric field.  ζ is the zeta 
potential at the shear plane, which can be derived from our previously calculated surface 
charge density (σ) via the Grahame equation31: 
 
η 
ζ ε E 
υeof  =  (eq. A8), 
Mechanical Power =    1  (ρυeofA)υ2  eof            (eq. A7), 
2 
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where kBT is the thermal energy, and n0 is the ion charge density within the 
nanochannels. This gives an electroosmotic velocity of 3.25x10-4 m/s at a source-drain 
bias of 1 volt.  
The electroosmotic current (Ieof) can be determined from the electroosmotic 
velocity value by 
 
where S is the cross-sectional area of all 80 nanochannels, resulting in a value of 1.5 
picoAmps. This makes up roughly 10 % of the total experimentally measured current of 
14.4 picoAmps at 1 volt, although electroosmotic flow has been theoretically shown to 
contribute up to 25 % of ion current in nanochannels32.  
Thus, assuming that electroosmotic flow accounts for between 10 % and 25 % of the 
total current, a linear extrapolation of the current from the no-slip, low bias region to 
higher voltage values results in an electroosmotic velocity of approximately 0.008 – 0.02 
m/s at 25 volts. Extracting out the slip-enhanced velocity from the current in the 
experimental KCl I-V curve with Vg = +15 V shown in Figure 2.5 using eq. A10 gives a 
value of ~1.7 m/s at 25 volts. We assume that electroosmotic flow dominates the current 
above the slip threshold voltage, so that the velocity value of 1.7 m/s is the 
electroosmotic velocity. Therefore, fluid velocity is enhanced about 80 – 200 times.  
Ieof = n0υeofS     (eq. A10), 
e ζ n0 [cosh        - 1] 
π 
ε kBT σ2 =  kBT  (eq. A9), 
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We can convert the velocity increases into mechanical power enhancement using eq. 
A7 above, which shows that mechanical power increases as the cube of the 
electroosmotic fluid velocity. Comparing slip-enhanced fluid flow to fluid transport 
confined by the no-slip boundary condition results in a calculated mechanical power 
output enhancement factor of approximately 5 – 6 orders of magnitude at 25 volts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
2.9 Appendix D: Differential Conductance of Potassium  
 Chloride 
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Chapter 3 
Plasma Proteome Profiling of Glioblastoma 
Multiforme using DNA-Encoded Antibody 
Microarrays: Characterizing Biomarker 
Signatures of Disease and Treatment Response 
 
 
 
3.1 Introduction 
Glioblastoma multiforme (GBM) [WHO grade IV astrocytoma] is the most 
common primary brain tumor in adults and the most aggressive form of glioma1. Due to 
its highly proliferative and infiltrative nature, GBM carries the poorest prognosis of any 
cancer, with a median patient survival of ~12 months, despite major advances in 
chemotherapy, radiation therapy, and surgery over the last few decades2. Although 
glioblastoma patients share many disease features in common, the fact that patients can 
differ tremendously in their response to therapy suggests that the cancer is molecularly 
heterogeneous. Indeed, it is known that genetically, there are two routes of glioblastoma 
development. Primary or de novo GBM, which is typically characterized by sudden onset 
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of high grade malignancy and an older age of onset, involves EGFR amplification and 
inactivation of the PTEN gene due to loss of heterogeneity at chromosome 103,4. 
Secondary GBM, which is defined by progression from a lower-grade astrocytoma, and 
often presents at a younger age, initially involves chromosome 17 deletions and 
inactivation of the p53 gene, followed by a series of other mutations as the tumor 
undergoes malignant transformation2-4. However, even within these two broad categories, 
patients differ in the types of subsequent chromosomal alterations and mutations their 
tumors exhibit, as well as in rates of tumor growth and progression, overall survival, and 
types of treatments to which they respond.  
Gene expression profiling has been instrumental in further elucidating key 
molecular players involved in GBM growth and progression, as well as the supporting 
cast of molecules that exhibit less pronounced changes5,6, greatly facilitating the search 
for candidate GBM biomarkers. However, gene expression profiling provides a window 
only to RNA expression levels, whereas much of the information processing within the 
cell occurs at the level of protein network interactions. Often the relationship between 
RNA and protein expression level is nonlinear7 due to additional transcriptional and post-
transcriptional controls8,9. Therefore, key drug targets could be differentially expressed at 
the protein level but not the RNA level10. In addition, post-translational processing and 
modifications can alter the activities of proteins and their locations within the cell8. This 
information cannot be obtained solely by profiling gene expression. 
Proteomic approaches pick up where genomic approaches leave off by allowing 
one to survey disease-related changes in global protein expression, find correlations 
between proteins that are similarly differentially expressed, and analyze those changes in 
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the context of known or prospective protein signaling pathways and networks. In 
particular, antibody-based microarray technology has facilitated the simultaneous high-
affinity profiling of numerous proteins from relatively small samples of cell and tissue 
lysates, culture media7, and bodily fluids, such as blood11, urine12, saliva, tears13,14,   and 
cerebrospinal fluid15. The advantages of this form of multiplexed protein detection over 
other approaches, such as 2D-PAGE and mass spectrometry, are its higher throughput 
and sensitivity, scalability, ease of use, cost-effectiveness, smaller sample requirements 
(< 50 µL), straightforward protein quantitation, and its ability to detect low abundance 
plasma proteins without the need for tedious protein fractionation steps7,11,16. As such, 
this technology represents a promising platform for novel disease-biomarker discovery. 
In addition, because small quantities of sample are sufficient to obtain enormous amounts 
of information, new opportunities are afforded for minimally-invasive diagnosis, 
stratification, and monitoring of cancer patients16.  
Blood is an ideal fluid for minimally-invasive detection of cancer-associated 
markers17. Cancer cells, like any other cell, secrete proteins into the bloodstream that can 
provide important information about their physiological and pathological state17. As well, 
intracellular proteins and cell-surface receptors are released into the circulation when 
cancer cells die. Antibody-based microarrays can permit the simultaneous, sensitive 
detection of many of these circulating factors from very small sample volumes – as little 
as a fingerprick’s volume worth of blood (10 – 50 µL)16. It might nevertheless be 
expected that plasma detection of brain tumor markers would be challenging because the 
blood-brain barrier (BBB) greatly limits the free passage of proteins and other molecules 
between the two compartments18. However, the integrity of this barrier becomes greatly 
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compromised at sites of inflammation19 or neovascularization20-22, which both typically 
accompany glioblastoma tumors. In addition, glioblastoma tumors secrete soluble factors 
that disrupt the blood-brain barrier23.  
Unfortunately, for the vast majority of cancers and other diseases, no biomarkers 
have thus far been discovered with adequate specificity and sensitivity for whole-
population screening or disease monitoring. Relatively few serum biomarkers have been 
FDA-approved for cancer monitoring, and just one – prostate specific antigen (PSA) – is 
approved for disease screening24. Likewise for glioblastoma, although gene expression 
profiling has allowed for the discovery of numerous protein biomarker candidates, none 
of these proteins on its own has achieved broad application for routine clinical diagnosis, 
prognosis, or monitoring of GBM, or for evaluating or predicting therapeutic response25.  
However, it has become increasingly recognized that large panels of proteins, in 
which each component protein has relatively poor disease specificity on its own, can, as a 
group, provide a highly sensitive and specific molecular signature of disease26,27. A 
number of studies have demonstrated the ability of antibody-based microarrays to 
identify protein expression patterns that can discriminate between patients with cancer (of 
the bladder28, pancreas29, prostate30, or stomach31) and normal controls. In theory, a 
sufficiently informative protein biomarker panel could stratify a given disease into 
subgroups based on unique molecular phenotypes, much as has been shown in gene 
expression profile studies5,10. Treatments could then be customized to the tumor’s 
specific set of molecular alterations. This would greatly contrast with the current 
expensive and time-consuming trial-and-error, watch-and-wait approach of administering 
a chemotherapeutic, awaiting a response, and then changing the medication if no 
48 
 
response is achieved. All the while, the patient’s tumor continues to advance in grade and 
stage.  
The routine use of antibody-based microarrays for multiplexed, high-throughput 
plasma biomarker detection and patient classification requires that these platforms be 
created using standardized methods that optimize sensitivity, reproducibility, cost, and 
compatibility with microfluidic chip based environments. While many approaches for 
arraying antibodies on slide surfaces have been investigated, DNA-directed antibody 
immobilization provides a number of unique advantages in this regard. For one thing, as 
compared to directly spotted antibodies, DNA-tethered antibodies exhibit less 
denaturation and possess greater orientational freedom, allowing a larger proportion of 
antibodies to be oriented such that their binding sites are accessible to cognate 
antigens32,33. Studies have also shown that this approach offers improved spot 
homogeneity and reproducibility, and far more economical use of antibody materials32. 
Importantly, for multiplexed point-of-care diagnostics, DNA-directed immobilization is 
amenable to microfluidic chip assembly because the antibodies can be arrayed 
subsequent to bonding of the PDMS stamp with the DNA-spotted slide – a thermal 
process that would otherwise destroy the antibodies16,33.  
The goal of the present study was to determine whether a plasma protein signature 
could be elucidated that would be able to differentiate patients with glioblastoma (n = 46) 
from healthy controls (n = 47) via a simple blood test that uses close to fingerprick 
volumes (≤  50 µL) of blood. We also sought to elucidate a plasma biomarker signature 
indicative of tumor growth – and, conversely, treatment response – in Avastin-treated 
GBM patients. Our platform consisted of capture-antibody arrays created by DNA-
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directed assembly within ELISA-like wells. These antibodies were targeted against 35 
distinct proteins known to be generally associated with tumor growth, survival, 
migration, invasion, angiogenesis, and immune-regulation. The platform allowed us to 
profile even low-abundance analytes (such as cytokines and growth factors) in plasma 
using microliter-scale sample volumes. We detected a number of proteins that were 
differentially expressed with high statistical significance (p < 0.05), allowing us to use 
these plasma biomarker signatures to classify patients into the aforementioned 
experimental and control groups with high sensitivity and specificity. 
 
3.2 Materials and Methods 
3.2.1 DNA-encoded antibody libraries (DEAL) technique 
The antibody assembly platform used here is based on the DNA-encoded 
antibody library (DEAL) method, which has been reported elsewhere by our group33. 
When DEAL is utilized to measure proteins, it is used as follows (Figure 3.5 in 
Appendix). Capture antibodies (CAs) against the protein of interest are chemically 
labeled with single-stranded DNA (ssDNA) oligomers, yielding ssDNA-CA conjugates. 
The coupling reaction is accomplished using succinimidyl 4-formylbenzoate (SFB, 
Solutink) and Succinimidyl 4-hydrazinonicotinate acetone hydrazone in N,N-
dimethylformamide (DMF) (SANH, Solulink) as conjugation agents to link amine 
termini on DNA oligomers to the amine side-groups of proteins. A size-exclusion column 
is used to purify the product by removing excess unreacted DNA molecules. Separately, 
the complementary ssDNA oligomers (100 µM in a 50 % DMSO/water mixture) are 
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spotted onto a poly-L-lysine coated glass slide (150 µm spots spaced 300 µm center-to-
center) using an array spotter (VersArray Chip Writer Pro, BioRad). Each spot also 
contains 10 µM of oligo M as a spot loading control. At the beginning of a DEAL protein 
assay, incubation of ssDNA-CA conjugates with the complementary spatially-patterned 
ssDNA array assembles the CAs onto those specific sites through DNA hybridization. 
This step transforms the DNA microarray into an antibody microarray that is ready for a 
protein sandwich assay. Biological samples (i.e. plasma isolated from human whole 
blood) can be applied onto the CA microarray and antigens can be captured. Finally, 
detection antibodies and/or fluorescent read-out probes are introduced sequentially to 
complete the immuno-sandwich assay. DNA oligomer sequences are chosen with 
appropriate melting temperatures to optimize 37 oC hybridization to complementary 
strands while minimizing cross-hybridization (< 5 % in fluorescence signal). 
3.2.2 Antibody array platform 
Our platform consists of ELISA-like wells assembled by bonding a PDMS slab 
with square holes to a poly-lysine coated glass substrate onto which 6 x 6 oligonucleotide 
arrays have been pre-spotted. Thirty-five distinct DNA-addressed antibodies are directed 
to their complementary spots during the assay. The assay wells accommodate up to 200 
µL of sample, but in fact, only about 20 – 50 µL are needed to obtain a reasonable signal-
to-noise. We used 50 µL of plasma for all of our assays. 
3.2.3 Multiplexed assays on patient plasma 
Each microarray well (12 wells/slide) was first blocked with 200 µL of blocking 
buffer – 3 % wt/vol bovine serum albumin fraction V (Sigma) in 150 mM 1x PBS 
51 
 
without calcium/magnesium salts (Irvine Scientific) – for 1 hour in a 37 oC incubator. 
The wells were then aspirated, and 50 µL of a cocktail containing 35 different DNA-
antibody conjugates (50 nM each) in blocking buffer were pipetted into the wells to 
transform the DNA arrays into capture-antibody arrays. After incubation at 37 oC for 1 
hour, the wells were aspirated, and then rinsed with blocking buffer 4 – 5 times to remove 
excess unbound conjugate. At this step, the wells were ready for the blood test. Fifty-
microliter undiluted plasma samples were added to each well and allowed to incubate for 
1 hour at 37 oC. The samples were then aspirated and each well was again rinsed 4 – 5 
times with blocking buffer. Next, a cocktail containing the 35 biotinylated detection 
antibodies (50 nM each) in blocking buffer was added to each well (50 µL) and was 
allowed to incubate for 1 hour at 37 oC. The wells were aspirated and rinsed 4 – 5 times 
with blocking buffer, followed by incubation of a solution containing 50 nM 
Streptavidin-Cy5 (eBioscience) and 50 nM M’-Cy3 for 1 hour at 37 oC. The wells were 
aspirated, and rinsed 4 – 5 times with blocking buffer. The PDMS well template was then 
peeled off the slide within a blocking buffer bath, and the slide was allowed to incubate 
in the bath for 1 minute at room temperature. The slide was then immersed in 150 mM 1x 
PBS, 1/2x PBS, and twice in deionized water in separate 50 mL falcon tubes for 1 
minute, 10 seconds, and 2 seconds, respectively. The slide was then spun dry and scanned 
by a fluorescence microarray scanner.  
3.2.4 Plasma collection and processing 
Blood samples were collected by standard phlebotomy techniques in 10 mL blood 
collection tubes containing ACD-A anticoagulant (BD Vacutainer yellow-top glass 
tubes). The samples were centrifuged at 1500 x g for 15 minutes, and the plasma was 
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collected and subdivided into 200 µL aliquots. Care was taken to ensure that plasma 
samples were frozen at -80 oC within 2 hours of collection to minimize degradation of 
plasma proteins by proteases. Each aliquot was thawed just once as needed. 
3.2.5 Data processing and statistics 
Post-assay, all array slides were scanned using a two-color laser fluorescence 
microarray scanner (GenePix 4200A Professional, Axon Instruments) at the same 
instrument settings – 70 % and 50 % for the laser power of the 635 nm and 532 nm 
channels, respectively. Optical gains were 550 and 500 for the 645 nm and 532 nm 
channels, respectively. Spot intensities were quantified with the software program 
GenePix Pro 6.0 using the fixed circle method. For each sample, the local background 
was subtracted from each spot, and the average and standard deviation were taken for 
each of the 35 sets of six repeated spots. A semi-global normalization method was used 
for chip-to-chip normalization. Briefly, the coefficient of variation (CV) was calculated 
for each analyte over all samples and ranked. The 15 % of analytes (5 analytes) with the 
lowest CV-values were used to calculate the normalization factor Ni  = Si/μ, where Si  is 
the sum of the signal intensities of the 5 analytes for each sample, and μ is the average of 
Si  from all samples. The dataset generated from each sample was then divided by the 
normalization factor Ni. Universally, all datasets contained at least 4 analytes that had 
comparable intensities to negative controls run in separate experiments. Therefore, the 
net intra-assay intensities were calculated by subtracting each background-corrected 
analyte intensity by the mean intensity of the 4 lowest-intensity analytes. Unsupervised 
two-way average linkage hierarchical clustering (Cluster 3.0) was then performed on an 
entire patient cohort data set, and the resulting heatmap and dendrogram were viewed 
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using Java TreeView. The statistical significance (both Mann-Whitney and t-test p-
values) of differential protein expression between experimental and control groups was 
analyzed using the AnalyseIt add-in for Microsoft Excel. This add-in was also used to 
generate box plots for each measured analyte across each study group. 
3.2.6 Classification of patients 
Two-by-two contingency tables and diagnostic parameters – sensitivity, 
specificity, negative predictive value (NPV), and positive predictive value (PPV) – were 
calculated by repeated random sub-sampling cross-validation. An Excel macro developed 
in-house was used to randomly assign 10 patients to a test set, leaving the remainder of 
patients as the training set. Unsupervised two-way average linkage hierarchical clustering 
(Cluster 3.0) was then performed on the entire patient cohort dataset (now containing 10 
unknowns) and the resulting heatmap and dendrogram were viewed using Java 
TreeView. The ten unknown patients were then manually classified as belonging to the 
experimental (Group A) or control group (Group B) based on the following decision rules 
(x = fraction of members within the unknown’s cluster that belong to same group): 
 
1. The minimum number of clusters incorporating the unknown and at least 5 other 
members is analyzed. If all members of this cluster fall into the same group (x = 
1), the unknown is classified as a member of that group with high confidence (this 
is considered a homogeneous zone). If x > 0.75, the unknown is still considered to 
be part of the majority group (with average confidence) but the cluster is no 
longer considered a homogeneous zone. If x < 0.75, then… 
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2.  The minimum number of clusters incorporating the unknown and at least 8 other 
members is analyzed. If now x > 0.75, the unknown is considered to be part of the 
majority group. If 0.5 < x < 0.75, the unknown is still considered to be part of the 
majority group, but with low confidence. In this case… 
 
3. The minimum number of clusters incorporating the unknown and at least 14 other 
members is analyzed using the same decision rules as in 2. 
 
4. If x ~ 0.5 after step 3, then the unknown remains unclassified and is removed 
from the analysis. Alternatively, an x ~ 0.5 is sufficient to remove the unknown 
sample from the analysis even if the unknown is grouped within a smaller cluster 
if the members of that cluster are closely correlated, yet far less correlated with 
the nearest neighboring cluster. 
 
5. If in step 1, the unknown is part of a cluster containing 4 or fewer members that 
are all highly correlated with each other relative to the nearest neighboring 
cluster, the unknown is assigned to the majority group with low confidence if 0.5 
< x < 0.66, average confidence if 0.66 < x < 0.75 and high confidence if x = 1. 
 
6. If two or more unknowns are nearest neighbors, these unknowns remain 
unclassified and are removed from the analysis. 
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This random sub-sampling was then repeated 10 times with replacement (100 
unknown events), such that some patients may have been randomly assigned to a test 
sample more than once, while others not at all. An Excel macro developed in-house then 
compared the predicted and actual classifications, and output the total number of true-
positives, false-positives, true-negatives, and false-negatives in a 2 x 2 contingency table, 
as well as the sensitivity, specificity, NPV, and PPV of the diagnostic evaluation. This 
constituted the full diagnostic evaluation for a dataset. For the two patient cohorts 
examined in this study, diagnostic evaluation was also performed on trimmed datasets 
consisting of subsets of n proteins (from the initial 35-protein panel) that exhibited the 
most statistically significant differential expression between experimental and control 
groups (where n = 3, 6, 9, 12, 16, 20, 25). For each dataset, points were plotted in ROC 
space (sensitivity vs. 1 – specificity) to assess the predictive power of the test.  
 
3.3 Results 
3.3.1 Evaluation of DNA directed antibody microarrays 
Preliminary experiments were run in advance to validate a set of 35 orthogonal 
oligos that exhibited minimal cross-hybridization (< 5%). In addition, the full panel of 
DNA-conjugated antibodies was validated with a set of cognate recombinants to ensure 
that there was minimal cross-talk between each recombinant and non-cognate spots. Each 
DNA spot was loaded with reference DNA (10 %), which, once hybridized with a dye-
conjugated complement, served as a DNA-loading control. For each oligo, the spot 
loading was highly consistent both across an entire slide as well as between slides. 
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The fluorescent readouts from all plasma samples assayed on the 35-plex 
antibody array platform were analyzed for spot homogeneity, reproducibility, and signal-
to-noise. A representative image of the fluorescent readout from a single assay well is 
shown in Figure 3.1. Each well contained a total of six repeats of 6 x 6 spot arrays (35 
antibodies + 1 green Cy3-conjugated reference oligonucleotide). The spots are circular, 
well-defined, and radially homogeneous. There was very little intra-assay variation in the 
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intensities of each set of 6 spot repeats. In addition, spot intensities tended to be highly 
consistent even between duplicate assays run on separate slides.  
3.3.2 Classification of GBM patients versus healthy controls 
We compared plasma samples from 46 GBM patients (72 samples: for some 
patients, plasma samples from multiple collection dates were available) with those of 47 
healthy controls with respect to the plasma levels of 35 different proteins known to be 
generally associated with tumor growth, survival, invasion, migration, and 
immunoregulation. Two-way average-linkage hierarchical clustering allowed these two 
groups to be discriminated with a sensitivity and specificity of 84 ± 15 % and 89 ± 31 %, 
respectively (Figure 3.2a). The heat map is divided into numerous islands of GBM 
patient, healthy control, and mixed population clusters without a clean separation 
between the two groups. We then sought to determine whether the diagnostic accuracy 
could be improved by removing those test samples from diagnostic evaluation that did 
not fall into highly homogeneous clusters (i.e. > 70% of the cluster members belong to 
the same group). Within the subpopulation of test samples that fell into highly 
discriminatory clusters, the sensitivity and specificity improved to 90 ± 14 % and 94 ± 8 
%, respectively, albeit with a diagnosable population size that was 70 % of the original. 
Among test samples that clustered entirely with members of a single group 
(“homogeneous zones”), the sensitivity and specificity both approached 100 %. Thirty 
percent of samples fell into one of these homogeneous zones, allowing that subpopulation 
to be diagnosed with near-perfect accuracy.  
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We then repeated the cluster analysis with a trimmed panel that included only the 
nine proteins with the most statistically significant (Mann-Whitney and t-test p-values < 
0.05) differential expression (Figure 3.2b). These included: MMP3, PDGF, IP10, 
IGFBP2, VEGF, IL13, GM-CSF, MMP9, and CRP. The resultant heat map shows far 
improved classification of GBM patients and healthy controls into two separate clusters, 
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with few misclassifications in each cluster. By using this trimmed protein panel, the 
sensitivity and specificity achieved were 88 ± 13 % and 97 ± 8 %, respectively. As 
before, those samples (20 % of the sample population) that did not decisively cluster with 
a particular group were removed from diagnostic evaluation, and the sensitivity and 
specificity among the resulting diagnosable population improved to 94 ± 10 % and 96 ± 8 
%, respectively. Again, both sensitivity and specificity approached 100 % among test 
samples that clustered within perfectly homogeneous zones.  
3.3.3 Diagnostic strength as a function of protein panel size 
The cluster analysis was repeated for n-protein subsets of the original 35 protein 
panel, where n = 3, 6, 9, 12, 16, 20, 25, & 35 of the most statistically significant 
discriminators of GBM and health status. Diagnostic test sensitivity, specificity, and 
positive and negative predictive values were calculated for each of these subsets. Those 
test samples that did not decisively cluster with a particular group were removed from the 
evaluation. As can be seen in Figure 3.3a, the sensitivity and specificity remain about 
level as one trims the panel from 35 to 20 proteins. Both parameters increase as the panel 
is trimmed from 16 proteins onwards, with a peak at 6 proteins, followed by a sharp drop 
as the panel size is reduced further. On the other hand, the percentage of samples 
evaluable increases steadily as one trims the panel from 35 proteins down to 9 proteins 
and then tapers off. Since the strength of a diagnostic test lies not only in its diagnostic 
accuracy but also in the percentage of the population it can evaluate, we designated an 
artificial parameter S to represent the product of a diagnostic value and the percentage of 
patients diagnosable for each n-protein subset. As can be seen in Figure 3.3a, this 
parameter increases steadily as the protein panel size is reduced, peaking at 9 proteins 
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and then falling off sharply. Therefore, the 9-protein subset appears to optimize test 
performance by achieving a high diagnostic accuracy while still maintaining the ability to 
diagnose a large fraction of the sample population. 
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The predictive power of each n-protein subset for classifying GBM patients and 
healthy controls can also be evaluated by plotting the true positive rate (sensitivity) vs. 
the false positive rate (1 – specificity) for each subset. As observed in Figure 3.3b, the 6- 
and 9-protein subsets yield points in ROC (Receiver-Operating Characteristic) space that 
are farthest in perpendicular distance from the 45o line, suggesting that this number of 
differentially expressed proteins maximizes the predictive power. Points for all protein-
panel subsets move farther from the diagonal line as the sample population is trimmed to 
include: only those samples in clusters that are highly biased – the great majority (> 70 
%) of members belong to either the GBM patient or healthy control groups (as in Figure 
3.3b ii); or, only those samples in clusters that are completely biased – all members 
belong to one of the two groups (as in Figure 3.3b iii). Perfect classification was 
achievable in both 6- and 9-protein subsets when analyzing only the subset of test 
samples that were located within perfectly homogeneous clusters. As a whole, the data in 
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Figure 3.3 shows that by performing cluster analysis on patient plasma samples assayed 
for the 6 or 9 proteins most significantly differentially expressed, a very high degree of 
predictive power could be achieved among samples in highly biased clusters. In addition, 
the 9-protein set optimized the predictive power and the number of patients diagnosable. 
Furthermore, a subgroup of these patients who fell into perfectly homogeneous clusters 
could be diagnosed with near certainty.  
3.3.4 GBM patients on Avastin – classification of tumor growth vs. no growth 
We then assayed plasma samples from GBM patients treated with the 
chemotherapeutic drug Avastin (Bevacizumab) with respect to the same 35-protein panel 
as before. Specifically, we compared 52 samples from 25 patients who exhibited tumor 
growth (according to MRI imaging) with 51 samples from 21 patients who exhibited no 
tumor growth since their last evaluation. Two-way average linkage hierarchical clustering 
allowed these two groups to be discriminated with a sensitivity and specificity of 74  ± 10 
% and 78 ± 19 %, respectively (Figure 3.4a). When only patient samples within highly 
biased clusters were analyzed (45 % of the total sample population), the sensitivity and 
specificity improved to 90 ± 11 % and 96 ± 8 %, respectively. The sensitivity remained 
the same but the specificity increased to 100 % when test samples only in perfectly 
homogeneous clusters were analyzed (20 % of sample population).  
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The heat map is divided into 3 main sections consisting of samples from: 1. 
patients whose tumors have grown since their last evaluation (recurrence); 2. patients 
whose tumors have remained stable since their last evaluation (no recurrence); and 3. a 
mixed population of patients exhibiting either possible, slow growth or no growth. The 
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patient samples were then clustered with respect to the 4 proteins that were differentially 
expressed with the highest statistical significance (Mann-Whitney/t-test p < 0.05). Figure 
3.4b shows clustering of patient samples into 3 main groups: 1. tumor growth; 2. no 
tumor growth; and 3. mixed population: consisting of both patients with and without 
tumor growth. Particularly notable is that serum levels of HGF and TGFβ1 appear to be 
highly upregulated in the tumor growth group as compared with the no growth group. 
The cytokines MIP1α and IL12 (not shown in the heatmap) are also highly upregulated in 
the growth group. In addition, VEGFR2 appears to be highly down-regulated, while IL2 
is only somewhat downregulated, in the growth group compared with the no growth 
group. The alterations in cytokine levels observed in the sera of patients with growing 
tumors with respect to non-growing tumors may not necessarily be attributable to 
changes in tumor production and secretion of these cytokines. Rather, they may actually 
reflect changes in systemic responses to the growing tumor, such as inflammatory-
associated or other immune-mediated responses. 
 
3.4 Discussion 
While antibody microarrays have been used in the past to profile cancers of the 
lung, liver, ovary, prostate, pancreas, colon, and bladder, this is the first study 
demonstrating their use for plasma profiling of glioblastoma. In this study, we have 
shown that by interrogating a relatively large panel of 35 plasma proteins, biomarker 
signatures could be straightforwardly elucidated that could differentiate GBM patients 
from healthy controls, and that could classify GBM patients treated with Avastin based 
on whether they were responsive to therapy. Furthermore, none of these proteins on its 
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own has been shown to be an effective biomarker for cancer diagnosis or for treatment 
response. Therefore, this study also reaffirmed past observations that large panels of 
proteins can serve as highly sensitive and specific biomarker signatures of disease, even 
when each component protein is a poor disease-marker on its own. 
The study also showed that the predictive power of patient classification by 
hierarchical clustering depended on the number of differentially expressed proteins 
analyzed. Tests that included those proteins that were statistically significantly 
differentially expressed (p < 0.05) had greater predictive power compared with tests that 
additionally contained large numbers of non-discriminatory proteins or compared with 
tests that contained too few discriminatory proteins. The implication for future biomarker 
signature discovery from large numbers of proteins is that variously sized subsets of 
differentially expressed proteins should be evaluated to find the optimally-sized set for 
maximal predictive power.  
In this study, the accuracy of test sample classification was also dependent on the 
fraction of members within the test sample’s cluster that belonged to the same group 
(experimental vs. control). Therefore, prediction accuracy improved when evaluating 
only those test samples in highly biased clusters, and approached 100 % within 
completely homogeneous clusters. Of course, the fraction of diagnosable patients 
decreased as the tolerance for cluster heterogeneity was reduced. In light of this, an 
optimal tolerance was chosen that maximized diagnostic accuracy while minimizing the 
fraction of patients left out of the diagnostic evaluation. In this study, we evaluated only 
three tolerance settings, corresponding to exclusion of test samples in clusters that were: 
i. perfectly heterogeneous, ii. < 70 % homogeneous, and iii. < 100 % heterogeneous. 
68 
 
However, the study could potentially be reanalyzed with a larger set of tolerances to find 
an even better optimum. Alternatively, all patients could have been included in the 
diagnostic evaluation, but with the appreciation that the diagnosis of patients in certain 
clusters would be more accurate than in others. In theory, an accuracy score or 
confidence level could be calculated for grouping within any cluster. Subsequently, only 
those patients whose diagnoses have a predicted accuracy greater than, say, 90 % would 
be triaged for therapy, whereas all others would have to undergo further tests to ascertain 
their diagnosis. Based on our results, the diagnostic accuracy would be expected to 
increase with the homogeneity of a test sample’s cluster, with even higher accuracies 
likely attainable in homogeneous clusters of larger size.  
Though it might have been anticipated that plasma protein detection of brain 
tumors would be difficult due to the blood-brain barrier, in fact, we were able to detect 
differential expression of a number of factors. Many of these have been associated with 
systemic cancers or have been previously shown to be differentially expressed in culture 
media from GBM cell lines and primary cells, in the CSF fluid of GBM patients, or even 
in patient sera. For example, VEGF, a powerful mediator of endothelial cell proliferation 
and angiogenesis generally, which was found to be upregulated in GBM patients in this 
study, has also been shown previously to be highly secreted from GBM cell lines and 
primary tumors and to be expressed in the CSF fluid of glioblastoma patients34. VEGF is 
typically associated with advanced tumor stage and poor prognosis in a variety of 
cancers34. While no difference in serum expression of VEGF in the context of GBM was 
found by some35, our results corroborate reports that have shown upregulated serum 
expression of VEGF36. VEGF is known to promote microvascular permeability34, which 
69 
 
likely plays a role in the enhanced BBB leakiness at sites of characteristically highly 
neovascularized GBM tumors, thereby permitting its detection (as well as detection of a 
whole host of other tumor-associated proteins) in the plasma.  
PDGF, which also has an important role in glioblastoma angiogenesis – 
particularly, in peri-endothelial cell recruitment37 – was found to be upregulated in 
Avastin-treated GBM patients with growing tumors in this study. This finding is 
supported by past studies that have demonstrated that PDGF and its receptor are co-
overexpressed in glioblastoma-derived cell lines as well as in primary GBM tumors, 
promoting neovascularization and tumor progression by an autocrine mechanism38,39.  
The fact that HGF levels were highly overexpressed in the sera of Avastin-treated 
GBM patients exhibiting tumor growth as compared to those with stable tumors confirms 
previous reports demonstrating that higher tumor content and CSF levels of HGF are 
correlated with increased tumor malignancy and poorer prognosis40. HGF has also been 
implicated in synergizing with VEGF to promote glioma angiogenesis and increased 
microvessel density, particularly by inducing endothelial cell proliferation41,42. It is also 
known that c-Met receptor activation by HGF enhances several oncogenic mechanisms, 
including cell cycle progression, proliferation, survival, migration, and invasion, and that 
GBM progression can be mediated by an HGF/c-Met autocrine loop41. Since tumors 
require extensive neovascularization for sustained growth, and considering the 
instrumental role HGF plays in GBM progression, its heightened presence in the plasma 
of patients with tumor growth seems sensible.  
Serum IGFBP2, a binding protein that regulates the bioavailability and bioactivity 
of IGFs, was also found to be upregulated in this study, corroborating past reports of 
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elevated serum and CSF levels of IGFBP2 in patients with GBM and higher grade 
gliomas generally43,44. IGFBP2 has previously been shown to be involved in tumor 
growth regulation both in vitro and in vivo, and to promote glioma cell migration and 
invasion45,46. Its increased expression has therefore also been associated with increased 
glioma malignancy and poorer patient prognosis43.  
The ability to detect these proteins in the blood is perhaps less surprising when 
considering the leaky nature of newly-forming blood vessels in and around a 
glioblastoma tumor20, as well as the inflammation-associated47,48 increase in BBB 
permeability in the tumor’s vicinity. Furthermore, not all the differentially expressed 
proteins detected are products of tumor cells. Many of these proteins, and particularly the 
cytokines, are likely secreted from inflammatory and immune cells located either in 
proximity to the tumor or much farther away, representing a systemic immune or 
inflammatory anti-tumor response. For example, GM-CSF, IP-10/CXCL-10, and IL13 
were all found to be highly expressed in GBM patient plasma as compared to healthy 
controls. In addition, IL12, MIP1α, and TGFβ1 were all found to be highly differentially 
expressed in Avastin-treated GBM patients with growing tumors as compared to those 
with stable tumors.  
Serum GM-CSF expression has previously been shown to be increased in GBM 
patients36. This is not surprising considering its important, yet conflicting, roles in 
promoting tumor proliferation, migration, and angiogenesis on the one hand36,49, while on 
the other hand stimulating myeloproliferation in order to mount an immune/ 
inflammatory attack against growing tumors48,49. Likewise, MIP1α and its receptors have 
been shown to be overexpressed in GBM cells in vitro, and likely serve to attract 
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appropriate subsets of inflammatory and immune effector cells – including lymphocytes 
and macrophages – to the sites of tissue damage for repair50. However, this antitumor 
activity may be outweighed by an autocrine loop that promotes proliferation of the tumor 
cells50. Differential upregulation of TGFβ1 in patients with growing tumors is consistent 
with studies showing that tumors, such as glioblastoma, can lose their cytostatic 
responsiveness to this cytokine, and can instead respond to it by producing PDGF, the 
tumor growth promoter mentioned previously. Alternatively, tumors can overproduce and 
utilize TGFβ1 to suppress an antitumor host immune response and evade immune 
surveillance51.  
The high expression of IP-10/CXCL-10 seen in GBM patients in this study could 
also reflect the immune system’s attempt to inhibit further tumor growth. This cytokine is 
secreted by monocytes, endothelial cells, and fibroblasts as a chemoattractant for 
recruitment of monocyte-lineage cells, T cells, and NK cells that can participate in an 
anti-tumor response52. In addition, it has previously been implicated in inhibition of 
angiogenesis52, which is vital for tumor growth. Because its upregulation is induced by 
IFNγ, it is believed to contribute to the IFNγ-dependent anti-tumor effects of IL1253. This 
is also consistent with the upregulation of IL12 observed in this study in Avastin-treated 
GBM patients with tumor growth as compared to those with stable tumors. Interestingly, 
it also has conflicting tumor-promoting and proliferative effects on non-transformed 
astrocytes and cultured glioma cells, and its presence has been correlated with increased 
malignancy grade54. However, its role as a discriminatory marker in this study may be 
confounded by the fact that our experimental population was older than the control 
population, and IP-10 levels naturally increase with age, doubling between ages 40 and 
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70 – 8055. Of all the analytes studied, IL13, a cytokine known to have both pro- and anti-
tumor effects, showed the highest GBM patient plasma overexpression. This may be 
attributable to IL13 insensitivity in GBM patients as a result of GBM tumor 
overexpression of the “decoy” inhibitory receptor IL13R𝛼𝛼256, which may be leading to a 
compensatory increase in IL13 production.  
Surprisingly, the levels of both CRP and MMP9 were actually decreased in GBM 
patient plasma as compared with healthy controls, and VEGFR2 levels were 
downregulated in Avastin-treated GBM patients with growing tumors as compared to 
those with stable tumors. Because of MMP9’s documented involvement in promoting 
tumor invasion, as well as its anti-apoptotic and pro-angiogenic effects57,58, its decreased 
plasma level in GBM patients in this study was unanticipated. Furthermore, the decrease 
in VEGFR2, a VEGF receptor, is unexpected since one-third of primary glioblastomas 
harbor amplifications in 3 receptor tyrosine kinase genes that are juxtaposed on 
chromosome 4: KIT, PDGFRA, and VEGFR259. Furthermore, past studies have shown 
that VEGFR2 (and VEGFR1) is highly expressed in primary GBM tumors60. However, 
VEGFR2 downregulation could be explained by the fact that these receptors are 
internalized by the cell when bound by ligand. Since VEGF levels are high, a significant 
amount of receptor internalization could be taking place. 
 
3.5 Future Outlook 
The fact that the plasma samples used in this study could be interrogated by 
multiplexed antibody arrays within ELISA-like wells allowed relatively small sample 
volumes ( < 50 µL) to be used. This suggests that these assays can in the future be 
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performed using blood from a fingerprick rather than the much larger quantities 
(milliliters) typically harvested by phlebotomy. In addition, the DNA-directed assembly 
of antibodies makes this platform amenable for use within microfluidics platforms, since 
DNA arrays can withstand the bonding temperatures required for platform assembly 
whereas directly-spotted antibody arrays cannot16,33. Therefore, a promising next step 
would be to integrate these arrays and antibody panels within a microfluidics-based blood 
separation diagnostic device. Because on-chip blood separation obviates the need for 
centrifugation and other blood processing steps, and due to the faster kinetics of ligand 
capture under conditions of fluid flow, all the assay steps within the microfluidic 
environment can be performed in under an hour. Consequently, a point-of-care diagnostic 
chip that probes for the most highly discriminatory proteins described herein for 
classifying patients into GBM or healthy subgroups (or for gauging treatment response) 
would allow patients to be diagnosed or monitored using a simple fingerprick blood test 
within a short time after walking into a doctor’s office. 
Future studies could also enlarge the microarray panel to hundreds of plasma 
proteins and evaluate even larger patient populations with varying grades of glioma. This 
could allow for higher resolution stratification of patients into diagnostic and treatment 
groups based on their molecular phenotypes, which could be more informative than 
histological grading alone. Additional studies could also assess the ability of these types 
of assays to classify patients as responders or non-responders shortly after initiation of 
treatment. Currently, using contrast-enhanced MRI imaging, it could take at least a week 
or more to discern whether a tumor is still growing or stable. However, it is likely that 
molecular changes within the tumor are occurring long before these changes manifest as 
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visible tumor growth and progression. Therefore, a blood test that could evaluate 
treatment response within hours of administration of a chemotherapeutic would allow 
doctors to arrive at the most effective treatment in the shortest possible time. The 
resulting benefits to the patient’s health as well as the cost-savings could be significant. 
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3.7 Appendix A: DNA-Encoded Antibody Libraries (DEAL) 
      Technique 
 
 
 
The advantages of DEAL are multifold. First, the fact that DNA hybridization is 
utilized as an assembly strategy allows for multiple proteins to be detected within the 
same microenvironment, since the various 1o CA antibodies for the various proteins to be 
detected can be each labeled with a different ssDNA oligomer (Figure 3.5).  Second, 
antibodies are not particularly stable, and this makes surfaces onto which antibodies are 
attached unstable towards drying out, heating, etc.  This means that the antibody must be 
attached to the surface immediately prior to use.  Using DNA hybridization as an 
assembly strategy means that the surface can be prepared ahead of time, dried out, 
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heated, shipped around, etc. The instability of antibodies also makes protein assays 
difficult to execute within microfluidics environments, since the antibodies don’t survive 
the microfluidics fabrication.  This is, again, circumvented with the DEAL approach.   
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3.8 Appendix B: Patient Characteristic Tables 
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3.9 Appendix C: Serum Protein Biomarker Panels and  
      Oligonucleotide Labels 
 
 
The protein panels used in the cancer-patient serum experiment (panel 1) and 
finger-prick blood test (panel 2), the corresponding DNA codes, and their sequences are 
summarized in Table 3.3 and Table 3.4. These DNA oligomers were synthesized by 
Integrated DNA Technologies (IDT), and purified by high pressure liquid 
chromatography (HPLC). The quality was confirmed by mass spectrometry. The 
antibody vendors and catalogue numbers are listed in Table 3.5. 
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Table 3.3. List of proteins and corresponding DNA codes_______________________ 
DNA-code Human Plasma Protein     Abbreviation  
Panel (1) 
A/A’  Interleukin-2      IL-2 
B/B’  Monocyte Chemotactic Protein 1    MCP1 
C/C’  Interleukin-6        IL-6 
D/D’  Granulocyte-Colony Stimulating Factor    G-CSF 
E/E’  Macrophage Migration Inhibitory Factor    MIF 
F/F’  Epidermal Growth Factor     EGF 
G/G’  Vascular Endothelial Growth Factor    VEGF 
H/H’  Platelet Derived Growth Factor    PDGF 
I/I’  Transcription Growth Factor alpha    TGFα 
J/J’  Interleukin-8      IL-8 
K/K’  Matrix Metalloproteinase 3       MMP3 
L/L’  Hepatocyte Growth Factor     HGF 
M/M’  Reference (Cy3)      M’-Cy3 
N/N’  Interferon-Inducible Protein 10    IP10/CXCL10 
O/O’  Stromal Cell-Derived Factor 1     SDF1 
P/P’  Insulin-like Growth Factor Binding Protein 2   IGFBP2 
S/S’  Insulin-like Growth Factor Binding Protein 5   IGFBP5 
U/U’  Macrophage Inflammatory Protein 1 alpha   MIP1α 
Z/Z’  Transcription Growth Factor Beta 1    TGFβ1 
AA/AA’  Chitinase 3-like 1      Ch3L1 
BB/BB’  Vascular Endothelial Growth Factor Receptor 3   VEGFR3 
CC/CC’  Tumor Necrosis Factor alpha     TNFα 
HH/HH’  Granulocyte-macrophage colony stimulating factor    C3 
II/II’  Matrix Metalloproteinase 2     MMP2 
JJ/JJ’  Interleukin-10      IL-10 
KK/KK’  Interleukin-1 beta      IL-1β 
MM/MM’  Interleukin-12      IL-12 
NN/NN’  Matrix Metalloproteinase 9     MMP9 
PP/PP’  Transforming Growth Factor Beta 2    TGFβ2 
QQ/QQ’  Granulocyte Macrophage Colony-Stimulating Factor  GM-CSF 
RR/RR’  C-Reactive Protein      CRP 
SS/SS’  Vascular Endothelial Growth Factor Receptor 2   VEGFR2 
TT/TT’  Interleukin-13        IL-13 
UU/UU’  Interleukin-23      IL-23 
VV/VV’  Serpin E1       Serpin E1 
WW/WW’  Fibrinogen      Fibrinogen 
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Table 3.4.  List of DNA sequences used for spatial encoding of antibodies__________ 
Sequence 
Name Sequence 
Tm (50mM  
NaCl) OC 
A 5'- AAA AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA-3' 57.9 
A' 5' NH3- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT-3' 57.2 
B 5'-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'- AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
F 5'-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA -3' 56.9 
F' 5' NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT -3' 56.1 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
I 5'-AAA AAA AAA ATG CCC TAT TGT TGC GTC GGA-3' 60.1 
I' 5' NH3-AAA AAA AAA ATC CGA CGC AAC AAT AGG GCA-3' 60.1 
J 5'-AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG-3' 56.5 
J' 5' NH3-AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA-3' 57.5 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-Cy3-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' NH3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
AA 5’-AAAAAAAAAATAAGCCAGTGTGTCGTGTCT-3’ 58 
AA' 5’NH3-AAAAAAAAAAAGACACGACACACTGGCTTA-3’ 58.1 
BB 5’-AAAAAAAAAAAGTCTGATCCCATCGCGTAT-3’ 57.8 
BB' 5’NH3-AAAAAAAAAAATACGCGATGGGATCAGACT-3’ 57.8 
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CC 5’-AAAAAAAAAAGAGGTCAGTTCACGAAGCTC-3’ 58.2 
CC' 5’NH3-AAAAAAAAAAGAGCTTCGTGAACTGACCTC-3’ 58.2 
HH 5’-AAAAAAAAAAGCACTAACTGGTCTGGGTCA-3’ 59.2 
HH' 5’NH3-AAAAAAAAAATGACCCAGACCAGTTAGTGC-3’ 58.4 
II 5'-AAA AAA AAA AGT CAG GTG TTC GCG CTC ATT -3' 60.1 
II' 5'NH3-AAA AAA AAA AAA TGA GCG CGA ACA CCT GAC -3' 59.4 
JJ 5'-AAA AAA AAA AGA TCG TAT GGT CCG CTC TCA -3' 58.8 
JJ' 5'NH3-AAA AAA AAA ATG AGA GCG GAC CAT ACG ATC -3' 58 
KK 5'-AAA AAA AAA AAC AGG TCA TCG AAC TCT CAG -3' 56.7 
KK' 5'NH3-AAA AAA AAA ACT GAG AGT TCG ATG ACC TGT -3' 57.5 
MM 5'-AAA AAA AAA AGG CGG CTA TTG ACG AAC TCT -3' 59.5 
MM' 5'NH3-AAA AAA AAA AAG AGT TCG TCA ATA GCC GCC -3' 58.8 
NN 5'-AAA AAA AAA AGC AGG GAA TTG CCG ACC ATA -3' 59.9 
NN' 5'NH3-AAA AAA AAA ATA TGG TCG GCA ATT CCC TGC -3' 59.1 
PP 5'-AAA AAA AAA ACG CGG CGT GTC TCA GAA TAT -3' 59.8 
PP' 5'NH3-AAA AAA AAA AAT ATT CTG AGA CAC GCC GCG -3' 58.9 
QQ 5'-AAA AAA AAA AAT CCG GTC TCA TCG CTG AAT -3' 58.2 
QQ' 5'NH3-AAA AAA AAA AAT TCA GCG ATG AGA CCG GAT -3' 58.2 
RR 5'-AAA AAA AAA AAA TGC TCA CAT CGC AGG TAC -3' 57.6 
RR' 5'NH3-AAA AAA AAA AGT ACC TGC GAT GTG AGC ATT -3' 58.3 
SS 5'-AAA AAA AAA AAC GCT AAT GAC GGC AGT GCA -3' 60.4 
SS' 5'NH3-AAA AAA AAA ATG CAC TGC CGT CAT TAG CGT -3' 60.3 
TT 5'-AAA AAA AAA AAT GTG TCC GAA CGT CGA GCT -3' 59.8 
TT' 5'NH3-AAA AAA AAA AAG CTC GAC GTT CGG ACA CAT -3' 59.8 
UU 5'-AAA AAA AAA AGC CGT CGG TTC AGG TCA TAT -3' 59.4 
UU' 5'NH3-AAA AAA AAA AAT ATG ACC TGA ACC GAC GGC -3' 58.7 
VV 5'-AAA AAA AAA AGT CGC GGG TTC TGC ACA TAT -3' 59.9 
VV' 5' NH3-AAA AAA AAA AAT ATG TGC AGA ACC CGC GAC -3' 59.2 
 
* All amine-terminated strands were linked to antibodies to form DNA-antibody conjugates using SFB/SANH coupling 
chemistry described by R. Bailey et al.33 Codes AA-HH were used in the experiment examining fresh whole blood from a 
healthy volunteer. Codes A-M were used for the molecular analyses of cancer patient serum samples. 
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Table 3.5.  Antibody vendors and catalogue numbers__________________________ 
 
Company 
 
 
  
 
 
Capture Antibody 
     (Catalogue #) 
Detection 
Antibody 
(Catalogue #) 
IL2  BD  555051  555040 
MCP1  eBioscience 
eBioscience 
 16-7099-85  13-7096-85 
IL6   16-7069-85  13-7068-85 
G-CSF  R&D systems  MAB214  BAF214 
MIF  R&D systems  MAB289  BAF289 
EGF  R&D systems  MAB636  BAF236 
VEGF  R&D systems  MAB293  BAF293 
PDGF  R&D systems  MAB1739  BAF221 
TGFa  R&D systems  AF-239-NA  BAF239 
IL8  BD  554718  554716 
MMP3  R&D systems  AF513  BAF513 
HGF  R&D systems  MAB694  BAF294 
IP10  R&D systems  MAB266  BAF266 
SDF1  R&D systems  MAB350  BAF310 
IGFBP2  R&D systems  MAB6741  BAF674 
IGFBP5  R&D systems  MAB8751  BAF875 
MIP1a  R&D systems  AF-270-NA  BAF270 
TGFb1  BD  559119  559119 
Ch3L1  R&D systems  DY2599  DY2599 
VEGFR3  R&D systems  MAB349  BAM3492 
TNFa  eBioscience  16-7348-85  13-7349-85 
C3  abcam  ab17455-100  ab14232-50 
MMP2  R&D systems  DY1496  DY1496 
IL10  eBioscience  16-7108-85  13-7109-85 
IL1b  eBioscience  16-7018-85  13-7016-85 
IL12  eBioscience  14-7128-82  13-7129-85 
MMP9  R&D systems  MAB9092  BAM909 
TGFb2  R&D systems  DY302  DY302 
GM-CSF  BD  554502  554505 
CRP  R&D systems  MAB17071  BAM17072 
VEGF R2  R&D systems  MAB3573  BAF357 
IL13  eBioscience  16-7139-81  13-7138-81 
IL23  eBioscience  14-7238-85  13-7129-85 
Serpin E1  R&D systems  MAB1786  BAF1786 
Fibrinogen  abcam  ab10066-250   ab14790-200 
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Chapter 4 
High-Density, Multiplexed Patterning of Cells at 
Single-Cell Resolution for Applications in Tissue 
Engineering 
 
 
“To further the construction of complex tissues, or even entire organs, there are still 
significant technical challenges to overcome. Among them, a very important problem is 
subtly combining and orchestrating cells, growth factors and scaffolds into an 
architecture that will allow their unfettered interaction, especially where distinct cell 
types are required in anatomically exact locations to attain biological function.”    
-Thomas Boland. Inkjet printing of viable mammalian cells. Biomaterials, 2005, 26, 93- 
 99. 
 
 
4.1 Introduction 
4.1.1 Advances in tissue engineering 
 Considerable advances in the design of functional replacements for damaged or 
destroyed tissues and organs over the last decade or so have created an avenue for 
overcoming both the shortage and immunogenicity of allogeneic transplants. Tissue 
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engineered substitutes for a number of tissues have already been created, including 
stomach1, esophagus2,  spinal cord3, and several types of commercially available skin. In 
addition, various types of cartilage, bone, and blood vessel replacements have been 
successfully implanted into humans4.  
Classical tissue engineering approaches have utilized a top-down approach, in 
which a solid scaffold mimicking an organ or tissue is first created, followed by seeding 
of cells on this scaffold5. While this method has been useful in a broad range of scenarios, 
its major limitations are difficulties in mimicking the native microarchitecture  (i.e., 
placing different cell types in precise positions relative to each other) and vascularizing 
large scaffolds for delivery of oxygen and nutrients to cells6.  
An alternative to this approach, which has been developed in recent years, is a 
bottom-up approach, in which cells are first patterned in an arrangement that closely 
emulates the native tissue microarchitecture, and these building blocks are then “stacked” 
together to create a functional tissue unit7. Examples of this include encasing patterned 
cells in thin layers of thermally- or UV-curable hydrogels, which are sufficiently rigid so 
as to maintain, intact, the architecture of patterned cells. These cell-laden hydrogels are 
then stacked on top of each other to create three-dimensional structures8.  
The success of cell culture and growth in these environments lies in the fact that 
hydrogels can closely mimic the tensile, elastic, and compressive physical forces a cell 
typically encounters within its native extracellular matrix (ECM) 9. In addition, hydrogels 
can be impregnated with ECM proteins that allow cells to attach to the extracellular 
matrix (be it native or synthetic), and which provide the chemical cues that anchorage-
dependent cells require for growth and survival9-11. Moreover, soft-lithography 
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techniques can be used to imprint vascular channels between cell-laden hydrogel layers to 
provide perfusion at the length-scales of the native microenvironment12.  
An important additional benefit that certain hydrogels can provide is their relative 
lack of immunogenicity, which could potentially allow allogeneic cells encased within 
them to be transplanted with minimal risk of detection by the host’s immune 
surveillance13,14. Capitalizing on this idea, many groups have sought to minimize or even 
eliminate the immunogenicity of allogeneic islet transplants by encapsulating donor β 
cells (insulin-producing islet cells) in hydrogel microcapsules made of non-immunogenic 
materials, such as alginate or polyethylene glycol (PEG) 15-17. These hydrogel capsules 
contain pores that are large enough to allow oxygen and nutrients to be transported freely 
for metabolic sustenance, but that are too small for entry of antibodies or T cells14. In 
principle, islets from other species (pigs, monkeys) could potentially be encapsulated, 
without the danger of graft rejection, allowing for an ample supply of islets to be 
harvested and transplanted10. In addition, human and non-human stem- and precursor- 
cells could be propagated in culture and then encapsulated for transplantation10,14.   
Of course, the potential advantages of encapsulation come with the challenges of 
ensuring cell survival in microcapsules over extended periods. Many groups have looked 
at ways of increasing the longevity of cells within these capsules by adding extracellular 
matrix proteins, tuning their size (smaller capsules have a smaller diffusion barrier) and 
porosity, and embedding molecules (such as VEGF) that accelerate vascularization of the 
transplants in rodent models.  
However, it is becoming increasingly recognized that these may not be the only 
factors that are essential to cell survival and function. In most tissues, cells require 
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chemical cues from particular types of adjacent cells (juxtacrine signaling) and nearby 
cells (paracrine signaling) in order to survive and properly perform their functional roles. 
For example, in the central nervous system (CNS), glial cells receive inputs, assimilate 
information and send instructive chemical signals both to neurons and to other 
neighboring cells18,19. Astrocytes, in particular, have been implicated in dynamic 
regulation of neuron production, synaptic network formation, and neuron electrical 
activity20. Also, in endocrine glands, proper hormone secretion requires cell-cell 
communication for regulated and synchronous activity of all cells within the gland21,22.  
The human islet is no exception. Unlike the rodent islet, in which β cells cluster together 
in the islet center (forming an “insulin core”) while glucagon-secreting α cells and the 
less abundant δ and PP cells are relegated to the periphery, all endocrine cell types in 
human islets are interspersed together in a manner that is likely nonrandom (Figure 4.1). 
The multiple islet cell types are free to intermingle in “an arrangement which predisposes 
human islets for strong paracrine interactions23.” In order for native microarchitectural 
arrangements to be reproduced in synthetic constructs created from cultured islet or CNS 
cells, some method of patterning these various cell types in close proximity to each other, 
in the correct ratios, and with precise relative positioning is needed. 
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4.1.2 Challenges and limitations to high-resolution multiplexing 
Toward this end, microfabrication techniques borrowed from the semiconductor 
industry appear to hold the most promise. Microfabrication techniques have paved the 
way to breakthroughs in our ability to pattern cells at high resolution for applications in 
biosensing24,25, drug screening26,27, neural networks28, and artificial tissues29,30. Existing 
methods for patterning cells include microcontact printing31,32, inkjet printing6,33,34, 
switchable substrates35,36, elastomeric stencils37,38, microwells29,39, optical tweezers40,41, 
electrophoresis42, and dielectrophoresis8,43. A major limitation of most of these platforms, 
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however, is the multiplexing resolution – the resolution at which different cell types can 
be patterned. For example, microcontact printing can be used for dense patterning of cell-
binding proteins with low-micron to sub-micron feature sizes; however, in order to print 
distinct features adjacently, multiple inking and alignment steps must be performed. In 
addition, the loading density of biomolecules patterned by this approach is limited, as the 
platform is typically suited to printing monolayers. Dielectrophoresis has been 
successfully used to pattern complex two-dimensional cellular microstructures, including 
liver lobules8,43, but this approach does not appear as yet to be amenable to a high degree 
of multiplexing. Inkjet printing is an exciting approach to high-throughput biomolecule 
printing, but its application to cell printing is still being tested as there are unanswered 
questions regarding cell viability in the presence of the thermal and mechanical stresses 
associated with the printing process. In addition, the feature resolution of biomolecule- 
and cell-based inkjet printers (~60 – 100 µm) is not yet at the single-cell level6,33,34.  
While microfluidic patterning of substrates for highly multiplexed biological 
sensing has been demonstrated44, this technique has not yet been used for high-resolution 
multiplexing of cells. This is likely due to a number of limitations of current patterning 
schemes. In the most general case, multiplexed features are created by simply flowing a 
distinct oligo, protein, antibody, or other biomolecule or chemical into each channel 
within a microfluidic device. Since microfluidic channels are typically long and thin, they 
are well-suited to patterning high-aspect ratio features (long, thin lines or rectangles), but 
not low-aspect ratio features, such as the micron-scale squares or spots that would be 
needed for high density cell arrays. While it is possible in theory to pattern such features 
using modifications of the PDMS device architecture, these modifications do not come 
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without their own set of challenges. For example, one could envisage building a 
multilayer PDMS structure, such that each layer contains a fluidic network that feeds a 
unique biomolecule solution to a series of micron-sized spots in the patterning (first) 
layer45,46. However, the task of aligning multiple layers and creating vias connecting the 
layers reliably is extremely arduous, and therefore impractical for high-density 
multiplexing of more than 2 – 3 distinct molecules or cells.  
 
4.2 From High Density Microarrays to Single-Cell Resolution 
Cell Arrays 
 
4.2.1 Creating a dense multiplexed cell microarray 
Here we show a relatively straightforward method for circumventing these 
limitations in microfluidic patterning, thereby facilitating high resolution biomolecule- 
and cell-multiplexing, while minimizing the complexities of device fabrication and 
processing time. The approach involves creating a densely-patterned DNA-microarray 
that is then converted into a dense cell-microarray.  
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As shown in Figure 4.2, the small DNA microarray features are created in two 
sequential oligonucleotide flow-patterning steps, as follows: 1. A PDMS device 
containing a high density of parallel channels is used to flow-pattern distinct oligo strands 
(“anchor strands”) onto a polylysine-coated glass surface. 2. The PDMS stamp is then re-
oriented on the substrate 90o clockwise, and a distinct set of oligos are flowed into the 
PDMS device to create a series of n x m microarrays. These oligos are designed to 
include a 20-base pair “tail” that is complementary to one of the anchor sequences, and a 
20-base pair “head” with a unique sequence. As such, after the DNA patterning is 
complete, these oligos serve as intermediaries that bridge the anchor sequences with 
unique DNA-conjugated cells. For example, in the first patterning step, we flowed three 
80-mer anchor sequences – named A, B, and C – in 3 adjacent channels and 
simultaneously repeated this flow-patterning arrangement 6 times. In the second 
patterning step, we flowed three sets of 3 distinct bridging strands, also in 3 adjacent 
channels (one set per channel): first channel - strand A’-i (containing both a 20-mer “tail” 
sequence that is complementary to anchor strand A, and a unique 20-mer “head” 
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sequence i), B’-ii, and C’-iii; second channel - strands A’-iv, B’-v, and C’-vi; third 
channel – strands A’-vii, B’-viii, C’-ix.  This flow-patterning arrangement was also 
repeated 6 times simultaneously. The result was a series of thirty-six 3 x 3 arrays, in 
which each 3 x 3 array contained 9 distinct oligonucleotide “head” sequences (i, ii, iii, iv, 
v, vi, vii, viii, ix) that were available for binding of 9 distinct cell types conjugated to one 
of 9 complementary strands (i’, ii’, iii’, iv’, v’, vi’, vii’, viii’, ix’). The red squares in 
Figure 4.3a were created by hybridization of i’-Cy5 fluorescent DNA to the 3 x 3 array, 
while green squares were generated by hybridizing (ii’-ix’)-Cy3 to the array. By adding 
only A’-i, B’-ii, and C’-iii strands in the second patterning step, creating 3 x 1 arrays was 
straightforward (Figure 4.3b). Red squares, green squares, and yellow squares were 
created by adding i’-Cy5, iii’-Cy3, and equal concentrations of ii’-Cy5 and ii’-Cy3, 
respectively. The dimensions of the square DNA features comprising the arrays exactly 
equal the width of the channels used to pattern them. Therefore, since the PDMS flow-
patterning channels were 10 µm wide and spaced 30 µm apart, closely-packed 10 µm x 
10 µm DNA squares were created that could each accommodate a distinct ~10 µm-
diameter single cell. 
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To increase the total number of repeats of these 3 x 3 array units, the number of 
channels in the PDMS flow-patterning device can be increased, or the entire set of 
channels can be designed to wind up and down in serpentine fashion across the length of 
the device. For example, by creating serpentine channels with 10 turns, as opposed to 
straight channels, the number of array repeats can be increased 100-fold (102), to thirty-
six hundred 3 x 3 arrays.  
 Once the glass surface was patterned, distinct cell types, each conjugated to one 
of 9 “head”-complementary oligo sequences, were pipetted onto the surface, where each 
conjugated cell type bound to its cognate square. Once patterned, the cells were encased 
in a UV-curable PEG hydrogel so that their positions relative to each other were fixed. 
The cell-laden hydrogel was then cut into small sections and stacked on top of each other 
with further curing to create a three-dimensional tissue.  
101 
 
4.2.2 Platform design flexibility and patterning opportunities 
In some sense, each DNA square and its cognate cell can be thought of as the 
biological equivalent of a pixel on a CCD display. The number of possible cell patterns 
increases exponentially with the number of orthogonal microarray squares in each grid 
unit - just as the number of patterns that can be displayed on a digital screen scales with 
the number of pixels. The sizes and spacings of these biological pixels can be tuned by 
the microfabrication process. More specifically, the feature sizes and spacings can be 
modified by adjusting the microfluidic channel widths and inter-channel distances, 
respectively. To allow for physical contact between cells, the feature sizes and inter-
feature distances need only be downsized sufficiently. For example, by creating 5 µm-
sized square features with 5 µm spacings, a 10 µm-diameter cell attached to its cognate 
feature will overlap the space between features to a degree, allowing it to come in contact 
with a neighboring cell whose footprint is also larger than its cognate square. 
Furthermore, by varying the widths and spacings of channels within a microfluidic 
device, different-sized features can coexist within the same array, accommodating cells 
of different sizes. By increasing feature sizes sufficiently, distinct clusters, each 
containing a few homotypic cells, can be patterned adjacently.  
The feature geometries are also tunable to a large extent. For example, one can 
simply rotate the PDMS device in the second patterning step at an angle between 0o and 
90o to create parallelograms instead of squares. Rectangles can be created simply by 
using a microfluidic device in the second patterning step that has different channel widths 
compared with the device used in the first step. Alternatively, in one of the two patterning 
steps, a PDMS device can be used in which each channel consists of a series of connected 
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circles or triangles, allowing a variety of feature shapes to be realized even within the 
same array unit. Since feature geometry has been shown to influence stem cell fates32, 
creating customized feature geometries for each cell type to be arrayed would be very 
valuable in cases where stem-cells or progenitor-cells are used to pattern tissues. With the 
flexibility in feature sizes, spacings, and geometries potentially afforded by this platform, 
dense 2-D microarchitectures can be patterned with feature proximities that permit 
contact between single cells of varying types, closely mimicking the native tissue 
environment. 
4.2.3 DNA conjugation of cells 
 In order for a cell type to be addressed to the correct square in a densely-patterned 
microarray, each cell type had to be labeled with a unique complementary 
oligonucleotide strand. Previous studies have shown variations of this method.  One study 
showed that oligos could be modified with lipophilic end groups that could anchor the 
oligos directly into the cell membrane. Bertozzi et al. demonstrated the attachment of 
ssDNAs to cell-surface glycans by means of Staudinger ligation chemistry, but the initial 
step required a 3-day cell incubation period with an exogenous modified sugar metabolite 
to facilitate subsequent chemical steps47. More recent work by the same group showed 
that N-hydroxysuccinimidal (NHS) ester-modified DNAs could be reacted directly with 
amino groups on cell-surface proteins in under an hour48.  
Our approach to conjugating cells with DNA was relatively straightforward 
(Figure 4.4). Cells were biotinylated and then addressed via streptavidin-conjugated 
oligonucleotides. Our own lab’s extensive experience using cysteine-engineered 
streptavidin (SAC)-conjugated oligos, in conjunction with biotinylated MHC proteins, to 
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pull down antigen-presenting T cells, inspired this method49. Native streptavidin contains 
a lysine residue in close proximity to the biotin-binding pocket, such that amide coupling 
strategies for cross-linking DNA would alter the streptavidin-biotin binding capacity. 
SAC by contrast has been genetically engineered to incorporate a cysteine residue at the 
carboxy-terminus, away from the biotin-binding pocket, allowing DNA to be conjugated 
using maleimide chemistry only at this site (since cysteine residues are absent in native 
streptavidin)49. To tailor this strategy for DNA conjugation of cells, cells were first 
biotinylated (by reacting with NHS-biotin), followed by incubation with their respective 
SAC-oligos. The advantage of this method is its modularity and ease. The reaction 
between the SAC-oligos and the biotinylated cells occur immediately upon mixing, so 
any biotinylated cell can be instantly conjugated with an oligo of one’s choosing. For 
experiments in which cells were patterned on arrays containing different sets of DNAs, 
biotinylated cells were quickly reacted with the SAC-oligos relevant to each DNA array. 
In addition, once biotinylated, cells could in theory be passaged a few times and still 
retain enough surface biotins for sufficient DNA conjugation. This would permit fast 
DNA-conjugation of cells directly from the culture dish, obviating the need to repeat the 
biotinylation procedure before every experiment.  
Like the conjugation method exemplified by the Bertozzi group48, our cell 
conjugation method also constitutes a cell surface marker-free approach. Whereas past 
cell-patterning approaches utilized antibodies against cell-surface proteins to capture cells 
(e.g. immunopanning)50-52, these approaches are only practical if a cell-surface protein 
exists in sufficient abundance to allow the cell to be held down by surface-bound 
antibodies48. For a marker with less surface density, higher affinity antibodies would be 
104 
 
needed to capture cells. On top of this, producing high-affinity monoclonal antibodies is a 
time-consuming and expensive process with variable outcomes. By contrast, biotinylation 
of cells, followed by binding of SAC-oligos, is a simple, generalizable platform that can 
be used on any cell type, regardless of whether the cell has a targetable surface marker. 
The cell need only have surface amino groups, which are ubiquitous due to the 
abundance of membrane proteins. 
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4.2.4 Patterning human central nervous system and mouse pancreatic islet tissue  
          constructs 
 
We first applied our patterning methodology toward creating a cell model of the 
human nervous system by co-assembling neurons and astrocytes into designed structures. 
The human CNS and neuronal systems in general are composed of neurons and glial cells 
interspersed in specific spatial organizations that are vital for the development of these 
systems53. Prior to integrating both cell types together, we first separately demonstrated 
the spatially selective capture of single astrocytes and single neurons.  Primary human 
astrocytes were first encoded with ii’ DNA and then incubated onto a 3 x 3 DNA 
microarray. The astrocytes localized only to the ii DNA squares, with ~27 % of squares 
covered by one astrocyte each). The fraction of squares covered by two astrocytes was 
larger (~40 %) because the astrocytes exhibited rapid division in culture, thus astrocytes 
that were dividing but hadn’t completed mitosis could bind to a single spot (Figure 4.5a). 
Nonspecific binding of cells to non-cognate squares or to any other portions of the slide 
was not observed.  In some cases, 3 to 4 astrocytes were found on particular ii DNA 
squares, which could be due to variability in the size of the astrocytes as well as the fact 
that astrocytes tend to cluster into small groups in culture. Astrocyte division was 
observed to continue on-chip even after the cells were patterned. In a separate 
experiment, primary human neurons were patterned onto the iii DNA spot of a 3 x 1 
microarray (consisting only of oligo sequences i, ii, and iii as the capture sequences) to 
illustrate the extent of cell density (Figure 4.5b). A much higher percentage of the DNA 
squares (60 %) bound to only one cell relative to the astrocyte experiment since the 
neurons did not divide in culture. The cell-patterned slide was then incubated in media at 
37 oC. When reassessed after 2 days, the neuronal processes were observed to be actively 
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growing, demonstrating that the neurons were still viable. Once the neurons were 
established, primary human astrocytes conjugated to ii’ DNA were then incubated with 
the neuron-patterned slide and localized to their cognate squares. The final cell pattern 
consisted of multiple rows of primary human neurons and astrocytes spaced 30 µm apart, 
with each cell localized to a 10 µm x 10 µm DNA square (Fig. 4.5c). After incubation 
with astrocytes, it was clear based on cell morphology that the astrocytes were localized 
to the ii DNA squares, while the neurons remained on the iii DNA squares and did not 
move or get washed away from their initial designated locations. 
107 
 
 
We also explored the construction of model pancreatic tissues. Some 340,000 
people nationwide have diabetes mellitus type 1, which is characterized by loss of insulin 
production as a result of an autoimmune destruction of β cells within the pancreatic islets 
of Langerhans54. While pancreas transplants have proven to be effective in restoring 
normoglycemia in diabetic patients, this approach carries the risks attendant to major 
surgery and lifelong immunosuppression55. Allogeneic islet cell transplantation is a less 
invasive alternative, but typically is limited to patients with highly specific clinical 
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indications that are in addition to diabetes55. A promising alternative is to propagate and 
differentiate stem cells in culture into mature islet cells, thus yielding an unlimited 
number of transplantable cells56. However, all endocrine cell types in human islets, 
including the insulin-secreting β cells, the glucagon-secreting α cells, and the less 
abundant δ and PP cells, are arranged in apparently nonrandom architectures. We thus 
chose to explore our high resolution tissue engineering approach for mimicking the native 
islet microarchitectures.  
In an effort to build a tissue that closely emulates the arrangement of cells in the 
human islets of Langerhans, we created an islet construct that included two mouse islet 
cell lines (α and β cells) patterned on the iii and ii DNA squares, respectively, of a 3 x 1 
microarray with identical dimensions to that used for the neuron-astrocyte construct 
(Figure 4.6). As in the neuron-astrocyte cell patterning experiment, the α and β cells 
localized to their cognate DNA squares, typically averaging ~1 cell per square (~67 % of 
iii squares bound to only 1 α cell; ~87 % of ii squares bound to only 1 β cell). For every 
100 correctly patterned cells, on average, only 1 cell bound nonspecifically, although 
there were examples of 2 or 3 cells patterning on a given spot (Figure. 4.6a,b).  
We were able to designate a fraction of our arrays for conducting functional 
assays on the patterned cells. After the islet cells were patterned, i’ DNA conjugated anti-
insulin antibodies were incubated on the slide and allowed to hybridize to their cognate 
squares adjacent to the cells. The cells were incubated for 2 days to allow ample time for 
secreted insulin to bind to the anti-insulin antibody squares. The insulin assays were 
developed with biotinylated secondary antibodies followed by fluorophore-conjugated 
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streptavidin. The antibody squares fluoresced under confocal microscopy only when β 
cells were present (Figure 4.6a-c). 
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Finally, we applied our platform to create islet tissue constructs in a 3-D 
configuration in order to more closely mimic native islet structures. Prior studies have 
shown that cell patterns can be encased in thin UV-curable polyethylene glycol (PEG) 
hydrogels and stacked to form 3-D tissue constructs.8,57 In those studies, the cells are 
typically localized to the surface by nonchemical means such that cell-pattern transfer 
from the slide surface to the hydrogel layer is straightforward. In our case, the cells are 
chemically attached to the slide surface via DNA hybridization, and so it was not obvious 
that the cells could be readily transferred. However, we found that once the cell patterns 
were encased within a UV-cured PEG hydrogel, we were able to remove the cell-laden 
hydrogel layer from the glass surface without disturbing the cell pattern or damaging the 
cells. We aligned and stacked two such hydrogel layers to create a 3-D islet tissue 
construct (Fig. 4.7). This procedure could be repeated to build up multiple layers. 
Viability of the encased cells, as determined by calcein AM/ethidium homodimer 
(live/dead) staining, was confirmed after incubation in media at 37 oC for one week (Fig. 
4.7). However, as in previous studies8,57, cell division and mobility within the hydrogel 
matrix was not observed, likely due to the strong mechanical barrier provided by the rigid 
PEG membrane. The use of lower PEG concentrations or reduced UV light power would 
likely decrease this mechanical barrier, but at the expense of the rigidity needed to 
maintain the pattern integrity. 
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The ability of our platform to act as an on-chip multiplexed ELISA technology 
could allow for a multitude of applications on densely patterned islet cells. For example, 
insulin levels could be compared to those of a series of control cultures containing equal 
amounts of the same 2 cell types in an unpatterned mixture of similar cell density: 1. in a 
culture dish (single layer of adherent cells); 2. in a single layer of cells encased in a 
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hydrogel; and 3. in a stacked 3-D structure. An identical set of control experiments could 
be carried out on patterned cells. Comparing insulin levels between experiments 1 and 2 
would allow one to assess the effects on insulin-production of encasing islet cells in a 
hydrogel layer in both patterned and unpatterned scenarios. Comparing experiments 2 
and 3 would allow one to determine the effect on insulin production of stacking multiple 
2-D islet layers on top of each other (again in both patterned and unpatterned scenarios). 
Comparing patterned and unpatterned structures – be they un-encased, encased in a single 
hydrogel layer, or encased in a 3D hydrogel structure – would reveal whether maintaining 
the relative positions of the 2-cell types in 2-D and in 3-D has an effect on insulin 
production that differs from a structure containing a random mixture of the same cells.  
A fourth experiment could compare insulin production by patterned 3-D 
structures comprised of aligned vs. unaligned cell layers. The cell-laden hydrogel layers 
could be aligned to each other using alignment markers (and a mask aligner), so that a 
given cell type always encounters the same neighboring cell in the layer above it (for 
example, a β cell in layer 2 is always above an α cell in layer 1). Such an experiment 
would show whether maintenance of a set cell configuration in all 3 axes of a 3-D islet 
tissue construct is functionally important (e.g. has an effect on insulin production) as 
compared with just 2 of the 3 axes.  
A fifth experiment would compare insulin production by 3-D tissue constructs 
with that of islets isolated from a mouse. The mouse islets would be sectioned such that 
they contain the same number of cells as the engineered tissues. In all of the experiments 
just mentioned, glucagon functional assays could be performed for the other cell type (α 
cell) as well. 
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Furthermore, two-color fluorescence immunostaining for insulin and glucagon (α 
and β cells, respectively) could be performed on cut sections of the patterned single-layer 
and 3-D constructs on a routine basis. The intensity and distribution of immunostaining in 
these sections could provide additional functional information that ELISA could not. For 
example, on chip ELISA assays may not be sensitive enough to detect insulin production 
from a relatively small number of patterned cells. In addition, if insulin levels in the 
tissue media are low, it would be useful to know whether the problem is that: 1. the β 
cells are producing little or no insulin, or 2. the β cells are producing insulin but cannot 
secrete it. Both of these scenarios would be problematic in the context of a transplant, and 
would require further tinkering with the design parameters. Immunostaining would also 
show whether cells have migrated or otherwise deviated from their original configuration 
on the slide or in the hydrogel. These experiments could continue to be repeated for at 
least a month or for as long as the cells are viable.  
 
4.3 Experimental Methods 
4.3.1 Mold and device fabrication 
Briefly, a 5-inch chrome mask drafted with the mold design (using AutoCAD 
software) and 4-inch silicon wafers were sent to a semiconductor processing foundry 
(Integrated Systems, Inc. ISSYS) for DRIE processing to create a silicon hard mold with 
40 µm thick features. The design consisted of a series of twenty 10-µm wide serpentine 
channels (with 3 turns) spaced 30 µm apart. The hard mold was then placed in a 
chlorotrimethylsilane (TCMS) vapor chamber for 20 minutes. A PDMS mixture (10 parts 
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Sylgard 184 A:1 part Sylgard 184 B curing agent) was poured onto the mold in a petri 
dish, degassed for 1 hour in a vacuum dessicator, and then baked at 80 oC until the 
samples were softly cured (~20 min). The PDMS mold replica was then cut out of the 
bulk PDMS and through-holes were punched at the locations of the channel inlets and 
outlets. The microfluidic mold replica was then rinsed with IPA and DI water, airgun 
dried, and dust was removed with scotch tape. The device was then centered on a clean 
polylysine-coated glass slide and bonded by baking for 4 hours at 80 oC. 
4.3.2 Validation of oligonucleotide set 
The oligonucleotide sequences were chosen based on a pre-validated set of 12 
orthogonal 40-mer oligos, each containing a unique 20-mer sequence followed by a 20-
mer poly-A tail. These oligos had originally been screened for having very low calculated 
melting temperatures for hair-pin structures, self-hybridization, and cross-hybridization. 
Three of the sequences served as anchor sequences, with their complements serving as 
the “tail” portions of the bridging sequences. The other 9 sequences served as the “head” 
portions of the bridging sequences, with their complements serving as the conjugate 
strands for the cells. The 20-mer head and tail sequences were appended to each other via 
a 20-mer polyA sequence, creating a 60-bp bridging sequence. For the anchor 
oligonucleotides, a length of 80 base pairs (two identical 40-mer sequences (appended 
end-to-end) was found to be optimal in ensuring sufficient contact area with the 
polylysine surface to anchor the cells. 
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4.3.3 First flow-patterning step 
1. 100 µM solutions of oligos A, B, and C (“anchor” sequences) were flowed into 
channels 1, 2, and 3 respectively. This was simultaneously repeated for each 
additional set of three channels. The solutions were flowed in at around 3 psi via 
external 23-gauge pin adapters connected to Tygon lines, which were hooked up 
to an external pressure source and pressure gauge. The solutions were flowed 
until 1 µL droplets formed at the outlets, indicating the channels were completely 
filled. 
2. The device was then stored in a dessicator at room temperature for 2 days to allow 
for complete evaporation of water, leaving behind the DNA stripes on the 
substrate. 
3. The PDMS was then peeled away and the patterned glass slide was baked at 80 oC 
for 2 – 4 hours to facilitate DNA bonding to the polylysine-coated slide. 
4. In the meantime, a second PDMS mold replica was fabricated and rinsed 
thoroughly with IPA and DI H2O, then airgun dried, and dust was again removed 
using scotch tape. 
5. Once removed from the oven, the slide was allowed to cool to room temperature 
and rinsed briefly with DI H2O to remove excess salts and unbound DNA, then 
dried with an airgun. 
6. The second PDMS mold replica was then placed on the patterned slide oriented 
90o-clockwise with respect to the original position of the first PDMS mold replica 
in the first patterning step. 
7. The device was then baked at 80 oC for 4 hours (for stronger bonding) 
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4.3.4 Second flow-patterning step 
1. 3 % BSA/PBS blocking buffer was then flowed into all device channels for one 
hour at 3 psi. 
2. For 3 x 3 Arrays: Solutions 1, 2, 3 (bridging sequences) were flowed into 
channels 1, 2, and 3, respectively, for one hour at 3 psi. This was simultaneously 
repeated for each additional set of three channels in the device. Solution 1: 50 µM 
each of oligo strands A’-i, B’-ii, C’-iii; solution 2: 50 µM each of oligo strands 
A’-iv, B’-v, and C’-vi; solution 3: 50 µM each of oligo strands A’-vii, B’-viii, 
and C’-ix. 
3. For 3 x 1 Arrays:  Solution 1 was flowed into multiple adjacent channels.  
4. 3 % BSA/PBS buffer was then flowed into each channel for 1 hour to remove 
excess unbound DNA. 
5. The PDMS was then peeled off, and the slide was incubated in a 3 % BSA/PBS 
bath (to block areas previously in contact with the PDMS), followed by rinsing 
with PBS, and airgun drying. (Rinsing with DI water was avoided at this step 
because it could dissociate the hybridized anchor and bridging strands). 
4.3.5 DNA microarray validation 
Once these DNAs were patterned into densely packed 3 x 3 grids or 3 x 1 grids, 
the patterned slide underwent a second cross-talk validation assay (now using just the 9 
dye-conjugated complements i’ through ix’) to ensure that no new crosstalk had been 
introduced by having two orthogonal sequences tethered into a single bridging sequence. 
This assay also served to assess whether there was leakage between microfluidic 
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patterning channels, which would manifest as smearing of the fluorescent signal between 
oligo squares in the grid. 
4.3.6 Conjugating cells with DNA 
1. Prior to conjugation, media was decanted from the cell culture dishes and the 
dishes were rinsed 3 times with 1x PBS. 
2. Each dish was then incubated at room temperature for 10 minutes with 3 mL of a 
40 µM solution of NHS-biotin in PBS (Solulink protocol). 
3. The culture dishes were then rinsed 3 times with media to remove excess 
unreacted biotin. 
4. 3 µL of 1 mg/mL SaC-oligo in 1 mL of 3 % BSA/PBS was added to each dish, 
followed by incubation at 37 oC for 5 minutes. The biotin-streptavidin binding 
reaction is complete in under 1 minute, but the reaction can proceed longer 
without causing harm to the cells. iii’-SaC was used to address α cells and 
neurons; ii’-SaC was used to address β cells and astrocytes. 
5. The culture dishes were then rinsed again with 3 % BSA/PBS 3 times to remove 
excess unbound SaC-oligo. 
6. 3 mL of warm (37 oC) trypsin was added to each culture dish and allowed to 
incubate for 3 minutes at 37 oC (to detach cells), followed by 5 mL trypsin-
neutralizing solution and 5 mL of media. 
7. Each cell suspension was then centrifuged at ~150 RCF for 5 min in a 15 mL 
falcon tube. The supernatant was aspirated, and oligo-conjugated cells were 
resuspended at a concentration of 10 million cells / mL in 2 µM EDTA in 3 % 
BSA/PBS.  
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4.3.7 Cell culture 
All cell cultures were incubated in a 37 oC humidity-controlled incubator with 5 
% CO2/95 % air. Mouse cell-line derived pancreatic α cells (alpha TC1 clone 6, ATCC, 
Manassas, VA) were cultured in DMEM (Invitrogen Cat. No. 31600-034) containing: 10 
% FBS (heat-inactivated), 15mM HEPES, 0.1 mM non-essential amino acids, 0.02 % 
BSA, 1.5 g/L sodium bicarbonate, 3.0 g/L glucose. Mouse cell-line derived pancreatic β 
cells (Beta-TC-6, ATCC) were cultured in 15 % FBS/DMEM. Experiments were 
conducted a week after plating. Human Primary Neurons (ScienCell Research Labs, 
Carlsbad, CA) were cultured in Neuronal Medium (ScienCell), and used for experiments 
2 days after plating. Human Primary Astrocytes (ScienCell) were cultured and continued 
to divide in Astrocyte Medium (ScienCell) and were used 4 days after plating. 
4.3.8 Cell patterning 
Serial Processing: 
1. Two distinct experiments were carried out, one with neurons and astrocytes and 
one with α cells and β cells 
2. 200 µL of a single oligo-conjugated cell type (2 million cells total) was pipetted 
onto a pre-blocked ultra-dense oligo-patterned slide, followed by incubation at 37 
oC for 30 min. 
3. The cell-patterned slide was then swirled lightly in 3 % BSA/PBS to remove non-
specifically bound cells. 
4. This procedure was then repeated on the same slide (either immediately or within 
a couple days) using the second oligo-conjugated cell type. 
119 
 
5. A dye-conjugated DNA reference marker (50 nM i’-Cy3) was added prior to 
patterning of the cells to assess whether the cells were binding to the correct 
squares (relative to the reference marker). 
4.3.9 Cell binding specificity 
To assess whether oligo-conjugated cells bind only to their cognate DNA spots 
requires either that the morphologies of the patterned cell types be sufficiently distinct to 
be discernable under conventional light microscopy, or that each cell type be labeled with 
a distinct (fluorescent) marker. In this case, neurons and astrocytes could be clearly 
distinguished based on morphology. Likewise, α and β cells could be easily distinguished 
based on morphology. However, if fluorescent labeling were desired, it could be 
accomplished prior to the cell-patterning step by labeling the two cell types with distinct 
membrane-permeable dyes (e.g. Blue, Yellow, or Red Cell-Labeling Solutions from 
Molecular Probes: DiO, DiI, and DiD). Based on the cells’ positions relative to the 
reference square (on examination under a fluorescent confocal microscope), one can 
straightforwardly determine whether each cell type has bound to the correct squares. 
Multiple array units can be examined to statistically analyze patterning reliability. 
4.3.10 Hydrogel encapsulation of cells8 
1. A 10 % solution of PEG-DA (MW 3400) in DMEM was filtered through a filter 
membrane with 0.2 µm pores. 
2. Separately, 30 mg of 2,2-Dimethoxy-2-phenylacetophenone (DMPA) 
photoinitiator was dissolved in 100 µL N-vinylpyrrolidone. 
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3. 10 µL of DMPA solution was then added to 1 mL of PEG-DA solution and 
vortexed. 
4. 150 µm-thick polished glass coverslips were then placed on the cell-patterned 
polylysine slide on either side of the cell-patterned area. A third coverslip was 
positioned such that it bridged the first two, creating a channel in which the cell-
patterned glass substrate served as the floor, and the 3 coverslips served as the 
walls and ceiling. 
5. The PEG pre-polymer solution was then pipetted into this channel and cured for 5 
minutes under a UV lamp at 4 mW/cm2 to form a thin (50 µm) hydrogel layer 
encasing the cells. The hydrogel layer was then peeled off keeping the cell pattern 
within intact. 
6. By stacking multiple such layers on top of each other either with or without 
alignment, a three-dimensional tissue-like structure could be created.  
7. The single-layer tissue or 3-D tissue construct was then placed in a culture dish 
with media. 
4.3.11 Cell function assessment 
Approximately 200 µL of a 5 µg/mL i’-anti-insulin Ab (R&D Systems, 
Minneapolis, MN) DNA-antibody conjugate in 15 % FBS/DMEM media solution was 
added to an islet cell patterned slide and allowed to hybridize to the squares of i DNA, 
followed by incubation at 37 oC for 2 days to allow insulin from nearby β cells to bind 
the conjugate.  The slide was then gently rinsed three times with media followed by 
addition of a 200 µL solution of 2 µg/mL biotinylated insulin detection antibody 
(GeneTex, Irvine, CA) in media, which was allowed to incubate at 37 oC for 1 hour. 
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Again, the slide was gently rinsed three times with media, followed by a 1 hour 
incubation at 37 oC of a 200 µL solution of 5 µg/mL streptavidin-Cy5 conjugate 
(eBioscience, San Diego, CA) for fluorescence detection. A final triple rinse with media 
was performed. 
4.4 Discussion 
The proper functioning of tissues depends on the precise architectural 
arrangement of various cell types, facilitating the types of cell-cell interactions necessary 
for cell growth, differentiation, survival, migration, and regulation of tissue function. 
Consequently, it is believed that by mimicking the cellular and extracellular 
microarchitectural arrangements found in native tissues and organs, it will be possible to 
engineer substitutes that exhibit the same or very similar functions. The ability to arrange 
cells and cell types at single-cell resolution, as shown here, would enable new 
opportunities to more accurately mimic complex microarchitectures, like those seen in 
pancreatic islets, nervous tissue, and other organs. 
It would be beneficial to see the islet cell construct function as well as native islet 
tissue. For one thing, human pancreatic islets consist predominantly of β (60 %) and α 
cells (30 %), with δ and PP cells constituting a small minority23. The construct shown 
here contains a distinct cell type on each of 2 squares in a repeating 3 x 1 array to 
demonstrate the multiplexing capability of the platform. As a result, both cell types are 
found in equal densities. This also means that, whereas native tissue consists 
predominantly of β cell / β cell, α cell / α cell, and α cell / β cell interactions, both cells 
types in the tissue constructed here could always interact with each other. Another 
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consequence of having equal numbers of each cell type is that the number of insulin-
secreting β cells per unit volume of tissue is lower than in the native tissue, which could 
impact the level of insulin secretion. Further diminishing the cell density per unit volume 
is the thickness of the hydrogel layers. Each 150 µm-thick hydrogel layer contains just a 
single layer of cells. Since the cells are about 10 µm in diameter on average, the resulting 
gap between cell layers in the 3-D construct is about 140 µm. This also results in 
intercellular contacts being possible only in the x-y plane but not in the z-direction.  
To address these issues, there are various ways in which islet structure can be 
more closely mimicked. Since cellular arrangement is hypothesized to affect cell viability 
and insulin production, future experiments could examine the effects of varying the 
pattern and distribution of the various cell types. These variations could include: 1. a 
checkerboard pattern of α and β cells (somewhat like the human or monkey islet), with or 
without interspersed δ and PP cells at regular intervals; or 2. an inner core of β cells 
surrounded by an outer mantle of α cells, and to a lesser extent δ and PP cells, as in the 
“core-mantle” model of the mouse islet23. The number of cells in the core and mantle can 
be tuned by adjusting the feature sizes, or by increasing the number of spots in each grid 
unit.  
Furthermore, methods of narrowing the spacing between layers could be explored 
so as to allow for cell-cell contacts in all three axes. The hydrogel layer thickness is 
determined by the thickness of the coverslips used as the templates. Once 10 µm-thick 
coverslips are attainable, the hydrogel layer thickness will permit cell contacts in all 3 
axes. In principle, an alternative would be to run a cell/PEG-prepolymer solution through 
a 10 µm-high microfluidic channel over the DNA patterned glass surface. Once the cells 
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bind to their cognate squares, the PEG matrix around them would be cured under UV. 
The PDMS would then be peeled off, leaving a 10 µm-thick cell-laden hydrogel stacking 
layer. In addition, since islets tend to assume a spherical glandular structure, the various 
layers could be cut into circular sections of varying radii which, when stacked, form 
hemispherical or spherical structures. Alternatively, a 3-D construct created from equal-
sized stacks could, upon completion, be cut or punched to produce numerous tiny 
cylinders, spheres, or hemispheres of tissue. 
Additional experiments could also explore modifying the extracellular 
environment and vascularizing the constructs to extend tissue longevity.  Covalent 
attachment of extracellular matrix proteins (collagen, laminin, fibronectin) or peptides 
(RGD, IKVAV) to the hydrogel matrix would more closely mimic the extracellular 
environment of islet cells and prevent anoikis (apoptosis due to lack of cell-cell or cell-
ECM interaction). To create much larger stacks of patterned hydrogel layers would 
require some mechanism of adequately perfusing the various layers since diffusion 
becomes limiting in hydrogel systems within a few tens of microns. This might be 
accomplished by lithographically imprinting capillary-like microchannels in each PEG 
hydrogel layer. Inlet and outlet holes could then be punched at either end of the 3-D 
construct, allowing perfusion of the imprinted capillary bed and its adjacent cells. 
Alternatively, a multitude of spherically-cut tissue sections could be packed into a rigid, 
hollow casing (like beads in a column) which can be perfused with media or blood. If 
hooked up to an arterial supply, the blood would permeate through the micron-sized 
spaces between the beads much as it would through capillary beds in real tissues. 
 
124 
 
4.5 Conclusion 
In summary, we have patterned ultra-dense DNA microarrays for multiplexed 
single cell resolution cell patterning with applications in tissue engineering. We created 
two tissue constructs, one made up of two human central nervous system cell types 
(neurons and astrocytes) and one consisting of two mouse pancreatic islet cell types (α 
and β cells). Cell viability was confirmed in both constructs, and cell function was 
established in the islet cell construct through the detection of insulin secretion.  In 
addition, islet cells were successfully transferred into PEG hydrogels and assembled into 
3D tissue structures. These results imply that this cell patterning technology has the 
potential to be utilized for tissue engineered implants in individuals with compromised 
organ function. 
 
4.6 Future Outlook 
In addition to enabling the engineering of constructs that mimic more complex 
native microarchitectures, this platform could also offer the unique opportunity to create 
customizable tissues with novel microarchitectures. In particular, this platform could 
facilitate precise positioning and contact between cells that might not ordinarily be found 
together in native tissues. For example, neurons could be patterned alongside stomach 
cells that produce obestatin – an appetite-suppressant protein – creating a tissue that 
could one day facilitate voluntary nervous system control over appetite suppression for 
obese individuals. Clearly, ligand and receptor modifications would have to be 
genetically engineered to allow for communication between cell types that ordinarily do 
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not communicate. Also, the numbers and ratios of cell types in an engineered tissue could 
be adjusted to optimize that tissue’s performance.  For example, the relative positions and 
ratios of oligodendrocytes and neurons patterned in a customized nervous tissue 
transplant could be adjusted to enable improved myelination, synaptic connections, and 
neuronal functionality.  
Given the multiplexing resolution that this technology enables, the door would be 
opened to a broad spectrum of other applications outside of tissue engineering. For 
instance, it would be possible to conduct cell-cell communication assays involving 
detection of cytokines or other secreted proteins from different types of single cells. To 
illustrate, a single glioblastoma (GBM) cancer cell and a single macrophage could be 
positioned at diagonal corners of a 3 x 3 array unit. The other 7 squares within the array 
could be occupied by a series of anti-cytokine and anti-growth factor antibodies. The 
cells could be given a specified amount of time (48 – 72 hours) to communicate in the 
presence of a stimulatory factor (like LPS), after which point labeled detection antibodies 
would be introduced and the intensities of each secreted cytokine measured. As a control, 
the same experiments could be conducted on each cell separately (equivalent of a highly 
multiplexed ELISPOT) to compare the relative contributions of each single cell secretion 
profile to the secretion of the dual-cell system. Because each of these 3 x 3 array units are 
repeated hundreds of times on a single slide, large sample sizes are afforded for statistical 
analysis.  
 This platform could also open up new opportunities in cell-based sensing, drug 
testing, and drug discovery, as assays could be performed on multiple tissue types on the 
same slide. For example, one could bond a PDMS stamp containing 10 separate channels 
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on top of the densely patterned DNA array. Different cell types and combinations could 
then be introduced into each microfluidic channel, where the conjugated cells would 
localize to their cognate squares, resulting in a different tissue type within each channel. 
Once cultured for a few days within the channels (under constant flow of media), a test 
drug could be introduced into each channel, and the outflow medium as well as the cells 
themselves could subsequently be analyzed. In this manner, drug effects could be 
straightforwardly tested on a number of different cells, cell combinations, or tissues 
simultaneously. 
 Finally, this patterning technology could be used for whole-genome or whole-
proteome analyses on minute sample sizes for research purposes or for point-of-care 
diagnostics (Figure 4.8). Considering the small feature sizes possible (10 µm squares 
with 30 µm pitch), a set of 40,000 genes or proteins could be profiled within a 
microfluidic channel that is 500 µm wide and a few centimeters long. Twice that number 
could be profiled in a channel with twice the length or width. Moreover, by varying the 
number of assay channels, multiple low-volume samples could each be assayed for 
thousands of genes or proteins on a single chip. 
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4.8 Appendix 
 
To validate that the designed oligo set was truly orthogonal, cross-talk assays 
were performed on the twelve oligos. First, the twelve primary strands were array-spotted 
on a polylysine-coated glass slide, baked at 80 oC for 2 – 4 hours, rinsed briefly with DI 
water, and airgun dried. A thin slab of PDMS with 12 pre-cut square holes was then 
bonded to the spotted glass slide, forming 12 assay wells. The wells were then blocked 
with 3 % BSA/PBS for an hour. Twelve solutions, each containing 50 nM of a distinct 
dye-conjugated complementary strand in 3 % BSA/PBS, were prepared and pipetted into 
the wells, such that each well was incubated with a different complementary strand for an 
hour. An additional complementary oligo (also at 50 nM) with a distinct dye color was 
added at this step as a reference marker. The same reference marker was used in all 
twelve wells. The wells were then rinsed with 3 % BSA/PBS, the PDMS was peeled off, 
and the slide was rinsed with 1x PBS followed by DI water, then airgun dried. The slide 
was then scanned using a fluorescent microarray scanner to determine if more than one of 
the twelve spots fluoresced, suggesting cross-talk. If this occurred, the sequence assayed 
would be considered insufficiently orthogonal to the rest of the panel and would be 
replaced by a different sequence. 
Our lab has previously validated a set of 12 orthogonal oligos, whose sequences 
(not including the 20-mer polyA tail) are shown below: 
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The first 3 sequences (A, B, C) can serve as the anchor sequences, as follows: 
  2X A-3’-polyA 
 ATCCTGGAGCTAAGTCCGTAAAAAAAAAAAAAAAAAAAAAATCCTGGAGCTAAGTCCGTAAAAAAAAAAAAAAAAAAAAA 
 2X B-3’-polyA 
 GCCTCATTGAATCATGCCTAAAAAAAAAAAAAAAAAAAAAGCCTCATTGAATCATGCCTAAAAAAAAAAAAAAAAAAAAA 
 2X C-3’-polyA 
 GCACTCGTCTACTATCGCTAAAAAAAAAAAAAAAAAAAAAGCACTCGTCTACTATCGCTAAAAAAAAAAAAAAAAAAAAA 
 
The complements to the anchors and the 9 remaining sequences can then be coupled  
together as follows: 
 
A ATCCTGGAGCTAAGTCCGTA A' TACGGACTTAGCTCCAGGAT 
B GCCTCATTGAATCATGCCTA B' TAGGCATGATTCAATGAGGC 
C GCACTCGTCTACTATCGCTA C' TAGCGATAGTAGACGAGTGC 
i ATGGTCGAGATGTCAGAGTA i' TACTCTGACATCTCGACCAT 
ii ATGTGAAGTGGCAGTATCTA ii' TAGATACTGCCACTTCACAT 
iii ATCAGGTAAGGTTCACGGTA iii' TACCGTGAACCTTACCTGAT 
iv GAGTAGCCTTCCCGAGCATT iv' AATGCTCGGGAAGGCTACTC 
v ATTGACCAAACTGCGGTGCG v' CGCACCGCAGTTTGGTCAAT 
vi TGCCCTATTGTTGCGTCGGA vi' TCCGACGCAACAATAGGGCA 
vii TCTTCTAGTTGTCGAGCAGG vii' CCTGCTCGACAACTAGAAGA 
viii TAATCTAATTCTGGTCGCGG viii' CCGCGACCAGAATTAGATTA 
ix GTGATTAAGTCTGCTTCGGC ix' GCCGAAGCAGACTTAATCAC 
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A'-i TACGGACTTAGCTCCAGGATAAAAAAAAAAAAAAAAAAAAATGGTCGAGATGTCAGAGTA 
B'-ii TAGGCATGATTCAATGAGGCAAAAAAAAAAAAAAAAAAAAATGTGAAGTGGCAGTATCTA 
C'-iii TAGCGATAGTAGACGAGTGCAAAAAAAAAAAAAAAAAAAAATCAGGTAAGGTTCACGGTA 
A'-iv TACGGACTTAGCTCCAGGATAAAAAAAAAAAAAAAAAAAAGAGTAGCCTTCCCGAGCATT 
B'-v TAGGCATGATTCAATGAGGCAAAAAAAAAAAAAAAAAAAAATTGACCAAACTGCGGTGCG 
C'-vi TAGCGATAGTAGACGAGTGCAAAAAAAAAAAAAAAAAAAATGCCCTATTGTTGCGTCGGA 
A'-vii TACGGACTTAGCTCCAGGATAAAAAAAAAAAAAAAAAAAATCTTCTAGTTGTCGAGCAGG 
B'-viii TAGGCATGATTCAATGAGGCAAAAAAAAAAAAAAAAAAAATAATCTAATTCTGGTCGCGG 
C'-ix TAGCGATAGTAGACGAGTGCAAAAAAAAAAAAAAAAAAAAGTGATTAAGTCTGCTTCGGC 
 
